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PREFACE 
 
In South Africa (SA), data on the specific cause of viral diarrhoea in children less than 5 years are 
mostly on rotavirus (RoV) and from hospitalized patients. A few studies have been carried out on out-
patient populations in SA to evaluate the relative importance of other enteric viruses like Norovirus 
(NoV). Hence, the precise epidemiology of these other virus-associated diarrhoea in children from the 
community in KwaZulu-Natal remains unknown. Epidemiological data are required to understand the 
contribution of other enteric pathogens, especially NoV, to diarrhoeal diseases in children. Studies on 
the characterization of NoV continue to produce important insight regarding the pathogenesis of NoV 
infection as well as in vaccine development and immunity. The introduction of commercial assays based 
on antigen detection by monoclonal antibodies and highly sensitive molecular techniques such as the 
real-time reverse-transcription polymerase chain reaction (RT-PCR) for NoVs in stool has improved 
the rate of detection of this pathogen. The study presented here was designed to detect human 
noroviruses among children 5 years and below attending King Edward VIII Hospital in KwaZulu-Natal 
(KZN), South Africa.  
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ABSTRACT 
 
Background - NoVs are single stranded RNA viruses belonging to the family Caliciviridae. They cause 
gastroenteritis in all age groups but mostly in young children and the elderly. They are classified into 
seven genogroups (GI – GVII) and only GI, GII and GIV infect humans. They cause self-limiting 
infection that resolves in approximately 10 – 50 hours after exposure. Symptoms include diarrhoea, 
vomiting, cramps, chills and headaches. Despite a high rate of vaccine coverage in KZN through the 
….., mortality among infants remains high. Therefore a study was conducted to describe the role of 
non-bacterial aetiologies of diarrhoea in children 5 years and under in KZN. This work investigates the 
contribution of NoV infection to this pathology. 
 
Methods - Stool specimens were collected between June 2014 and August 2014 from children 5 years 
and below presenting with diarrhoea to a regional hospital. Written informed consent was obtained from 
their parents or guardian. Demographic information was collected using a structured questionnaire. The 
specimen were tested for NoV antigen using Enzyme Linked Immunosorbent Assay (ELISA) and Real-
time Polymerase Chain Reaction (RT-qPCR) was used to detect viral RNA. The two methods were than 
compared with each other. 
 
Results - One hundred and eighty-two stool specimens were collected and tested for NoV. The 
prevalence of NoV when specimens were tested by ELISA and RT-qPCR was 10.4 % and 22.5 % 
respectively. The sensitivity of the ELISA in comparison to RT-qPCR was 24.4 % (95 % Cl: 12.4 – 
40.3 %) and the specificity was 93.6 % (95 % Cl: 88.2 – 97 %). The infection rate was highest in 
children within the age group of 12 – 24 months and all the NoV detected were of the GII genogroup 
 
Conclusion - NoV is a common cause of diarrhoeal illness in children presenting to the King Edward 
VIII Hospital. Genogroup GII dominated with 100 % of all positive NoV cases belonging to this group. 
Taking into consideration the low sensitivity of the ELISA test, the RT-qPCR would be more suitable 
for routinely testing stool specimens for NoV. An effective NoV vaccine is urgently needed. 
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CHAPTER 1 
 
INTRODUCTION 
 
NoVs are an important cause of acute gastroenteritis in all age groups, with the highest incidence among 
young children, elderly and immunocompromised individuals (Ahmed et al., 2014; Belliot et al., 2014). 
NoVs are small, non-enveloped single stranded RNA viruses that belong to the family Caliciviridae 
(Lopman et al., 2008). The infection is self-limiting in both healthy and immunocompromised 
individuals and resolves within 10 to 51 hours after exposure (Mans et al., 2016). The clinical 
presentation of NoV infection is characterized by watery diarrhoea along with vomiting, cramps, chills 
and headache (CDC, 2002).  No therapeutic treatment is currently available against NoV infection and 
the possibility of a vaccine is elusive as NoV could not be cultured until recently (Ettayebi et al., 2016; 
Ahmed et al., 2014). The introduction of RoV vaccine in many parts of the world has allowed NoV to 
become the leading cause of gastroenteritis in young children in most of these areas (Bucardo et al., 
2008; Payne et al., 2013) . 
NoVs are phylogenetically classified into seven genogroups (GI – GVII) based on the amino acid 
sequences (Payne et al., 2013; Zheng et al., 2006). Three of the genogroups are known to infect humans 
(GI, GII and GIV). Most human NoV outbreaks are caused by GI and GII, which are the genogroups 
with the largest genetic diversity. Genogroup GII-genotype 4 (GII.4) is the most prevalent type causing 
more than 95% of human NoV infections. Genotyping is based on the genetic makeup of an organism 
and human populations develope immunity against a specific genotype. This has caused the fast 
evolution and dominance of GII.4 with new strains evolving every two to three years replacing 
previously overriding strains (Vinjé, 2015; Hasing et al., 2013; Lopman et al., 2004). There has been 
major improvement in understanding the diversity and evolution NoV in the past decade (Eden et al., 
2014; Eden et al., 2013). Surveillance systems have been successfully implemented in developed 
countries including the United States of America and European countries resulting in a sharp increase 
in the reported NoV prevalence and diversity. On the other hand, low income countries like those in 
Africa have few NoV surveillance systems (Mans et al., 2016). Reports on NoV infection in Sub-
Saharan (Armah et al., 2006; Mans et al., 2010) and Northern Africa (Benmessaoud et al., 2015; El 
Qazoui et al., 2014) indicated the prevalence of NoV infection to be greater in children less than  5 
years compared to older children   (Siebenga et al., 2009; Smit et al., 1999). 
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In South Africa (SA), data on the specific cause of viral diarrhoea in children 5 years and below are 
mostly on Rotavirus and from hospitalized patients. A few studies have been carried out on out-patient 
populations to evaluate the relative importance of other enteric viruses like NoV  (Mans et al., 2010). 
Hence, the precise epidemiology of viral diarrhoea from children in the population remains largely 
unknown. Furthermore, SA studies focusing on the number and distribution of viruses responsible for 
diarrhoea in infants and young children are scarce. Viral and epidemiological data are required to further 
understand the association of diarrhoea in children to the different viral aetiologies including NoV. 
Most epidemiological information on viral diarrhoea in Africa is from hospitalized children. Few 
reports have been published on the viral species infecting children with mild to severe diarrhoea who 
are usually managed in outpatient clinics. This study was designed to determine the aetiology of 
diarrhoea in children attending King Edward VIII Hospital KZN, SA.  
 
 
1.1 Problem statement 
In South Africa (SA), data on the specific cause of viral diarrhoea in children 5 years and below are 
mostly on Rotavirus and from hospitalized patients using surveillance systems. A few studies have been 
carried out on out-patient populations in to evaluate the relative importance of other enteric viruses like 
Norovirus (Mans et al., 2010). Hence, the precise epidemiology of viral diarrhoea in out-patient children 
remains unknown. Furthermore, South African studies focusing on the number and distribution of 
viruses responsible for diarrhoea in infants and young children are scarce. Viral and epidemiological 
data are required to further understand the association of diarrhoea in children to the different viral 
aetiologies especially NoV. 
 
This study was designed to determine the prevalence detecting human NoV in children 5 years and 
below attending King Edward VIII Hospital in KwaZulu-Natal (KZN) as well as the best method for 
its detection. Studies on the characterization and discovery of NoV continue to produce important 
insight regarding the pathogenesis and development of immunity of NoV infection. The inability to 
cultivate human NoV in cell culture has hampered vaccine develoment. Of all causes of diarrhoea only 
RoV infection is currently vaccine preventable. Therefore, there is a need to investigate the contribution 
of other causes. The introduction of commercial assays based on antigen detection by monoclonal 
antibodies and highly sensitive molecular techniques such as the real-time reverse transcriptase 
polymerase chain reaction (RT-qPCR) as the diagnostic tools for determining the presence of NoV in 
stools, has increased the rate of epidemiological studies. It is important to determine the characteristics 
of circulating enteric viruses as a prerequisite to vaccine development and to the understanding of their 
genetic diversity in SA. 
 
3 
 
 
1.2 Aim 
The aim of this study was to detect human Noroviruses GI and GII among children of 5 years and under 
presenting with diarrhoea in KwaZulu-Natal, SA. 
 
1.3 Objectives: - 
 To detect human NoV using enzyme linked immunosorbent assay (ELISA)   
 To detect human NoV GI and GII using real time reverse transcriptase polymerase chain 
reaction (RT-qPCR) 
 To compare the result of RT-qPCR with that of the ELISA 
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LITERATURE REVIEW 
 
1.2.1 History and Discovery of Norovirus 
In 1929, Dr John Zahorsky, a paediatrician in St Louis proposed the term winter vomiting disease for 
an illness that was characterized by the sudden onset of diarrhoea and vomiting and the disease peaked 
during the cold winter months (Zahorsk, 1929). In October 1968, an outbreak resembling “winter 
vomiting disease” occurred at an elementary school in Norwalk, Ohio with high prevalence among 
teachers and students. This illness was characterized by diarrhoea, nausea and vomiting which resolved  
between 12 to 24 hours from the onset (Conly & Johnston, 2003). The causative agent of the outbreak 
was non-bacterial and was not cultivable, therefore viral aetiology was suspected (Adler & Zickl, 1969). 
As the virus, could not be grown in cell culture, the only alternative was to test it in human volunteers. 
Consequently, clinical studies were done using faecal filtrate free of bacteria to the viral hypothesis 
using faeces obtained from the Norwalk, Ohio outbreak. The volunteers did develop similar symptoms 
as the outbreak cases and the viral aetiology was confirmed. The virus was then named Norwalk agent 
and later Norwalk virus after the location where the virus was detected. In 1972, Kapikan and colleagues 
visualized the virus for the first time using immuno-electron microscopy (IEM) (Kapikian, 2000). They 
described the virus as non-enveloped small round structured viruses (27-32 nm in diameter) that caused 
gastroenteritis (Green et al., 2000). These small round structured viruses could not be cultured using 
existing tissue culture methodology and the nature of the virus remained obscure until molecular 
methods became available. In 1990, Norwalk like  virus (NLV) genome was described (Xi et al., 1990) 
which led to the development of PCR assays in 1992. With full access to the NLV genetic information, 
it became clear that, like most viruses, different geno-groups of NLV existed within a single genus, 
which eventually was termed NoV (Zheng et al., 2006). PCR assays were then introduced into clinical 
studies in patients with gastroenteritis and it became clear that the virus was responsible for more cases 
then previously described (Amar et al., 2007). Estimates indicate that NoV is responsible for 12% – 
40% of all gastroenteritis cases worldwide (Reuter et al., 2005; Amar et al., 2007; Patel et al., 2008; 
Ahmed et al., 2014).  
 
 
 
 
 
5 
 
1.2.2 Virology 
NoVs are a genetically diverse group of linear positive-sense single stranded RNA viruses that belong 
to the family Caliciviridae (Lopman, 2015). They contain a poly-adenylated RNA genome of ~ 7.7 kb, 
which is surrounded by an icosahedral non-enveloped capsid of ~ 27 nm in diameter (Jiang et al., 1993). 
The capsid comprises of single protein, arranged into 180 protein units in a T=3 symmetry. It consists 
of 45 % to 56 % guanine (G) + cytosine (C). NoV infect cells directly and, upon entering the cell, acts 
as messenger RNA (Tan et al., 2006). The 3’ end of the genome is poly-adenylated, resembling 
messenger RNA of eukaryote cells. The 5’ end is attached to a virus encoded protein known as VPg, 
required for infectivity  (Thorne & Goodfellow, 2014). NoVs have short untranslated regions (UTRs) 
at the end of each genome with Human NoV having 48 nucleotides at the 3’ UTR (Gutiérrez-Escolano 
et al., 2000; Karst et al., 2003; Pletneva et al., 2001). The UTRs contains conserved RNA secondary 
structure which are found all over the genome extending to the coding regions (Simmonds et al., 2008). 
All these structures are important in the translation, viral replication and pathogenesis of the NoV. 
Calicivirus are positive stranded RNA virus that replicate through the synthesis of a full length anti-
genomic strand using RNA dependent RNA polymerase (RdRp) that is translated initially from the 
RNA genome entry into the cell host (Clarke & Lambden, 1997).  The minus strand then acts as a 
template for the synthesis of a full length genomic RNA where non-structural protein are translated 
including the RdRp, helicase and protease (Simmonds et al., 2008).  
 
The NoV genome contains three conserved open reading frames (ORFs), except genome of Murine 
NoV which has a fourth ORF (Karst et al., 2014; McFadden et al., 2011a; Thackray et al., 2007). This 
fourth ORF has not been identified in any other NoV except Murine NoV Genogroup Five (Clarke & 
Lambden 2000; McFadden et al., 2011a). ORF1 (194kDa) encodes for a large poly protein which is 
cleaved by seven non-structural proteins that are involved in the replication of the genome (Sosnovtsev 
et al., 2006). The ORF1 is more than 5 kb in length making the first two-third of the genome. ORF2 
(60kDa) and ORF3 (23kDa) each encode for a  structural protein, Virion Protein (VP) 1 which is a 
major capsid protein is believed to participate in the identification of target receptors (Hardy, 2005). It 
contains two P domains (P1 and P2) and one S domains. The P2 domain contains an antigen presenting 
site and carbohydrate receptor binding region that may facilitate infection (Hardy, 2005). VP2 is a minor 
capsid protein that interacts with the RNA genome  when virion formation occurs (Herbert et al., 1996; 
Meyers et al., 1991; Morales et al., 2004; Herbert et al., 1997). NoV also contains a sub-genomic RNA 
identical to the last 2.4 kb of the actual genome (ORF2 and ORF3). The 5’ end of the sub-genomic 
RNA is attached to the VPg and the 3’ end is also attached to a poly-A-tail (Herbert et al., 1997). 
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Figure 1: Human NoV genome organization (Lopman, 2015). 
 
NoV is one of 5 genera within the Caliciviridae family. The other genera include Sapovirus, Lagovirus, 
Vesivirus and the most recent Nebovirus (Clarke et al., 2012). Sapovirus and Norovirus are the only 
genera that cause human gastroenteritis. Currently NoV is phylogenetically classified into seven 
Genogroups (GI – GVII) (Fig.2) based on the amino acid differences in the major structural protein 
(VP1) (Zheng et al., 2006; Vinjé 2015). Each of these genogroups can be divided into genetic clusters 
called genotypes. Three of the genogroups are known to infect humans (GI, GII and GIV). Most Human 
NoVs outbreaks are caused by GI or GII, which are the genogroups with the largest genetic diversity 
(Hansman et al., 2006). GII is the most prevalent genogroup, causing more than 95 % of human NoV 
infections. GIV can be also found in humans, while GIII and GV strains are found in cows and mice, 
respectively (Vinjé, 2015). Canine NoV is a recently discovered pathogen in dogs, with strains classified 
into genogroups IV and VI. NoV GII has 21 genotypes, GI has nine and GIV has two (Kroneman et al., 
2013).  
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Figure 2: Classification of NoV into seven genogroups (GI – GVII) (Vinjé, 2015) 
 
Since the mid-90s the majority of the global NoV outbreaks as well as sporadic cases have been caused 
by GII.4 viruses (Lopman, 2015). The evolution of GII.4 NoV and the development of new epidemic 
strains is caused by the mutation in the hyper variable region in the part of the genome that encodes the 
capsid which is the P2 domain of the 2nd ORF (Tan et al., 2003; Chen et al., 2004; Lindesmith et al., 
2008; Boon et al., 2011; Bull et al., 2010; Bull & White 2011). These mutations cause major changes 
in the epitope, causing the virus to be unrecognizable by the antibodies that have been acquired from 
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previous exposure (Bull & White, 2011). This process is known as epochal evolution, and was first 
described for influenza viruses to explain the emergence of epidemic strains (Lopman, 2015). 
 
1.2.3 Host susceptibility 
The cell tropism of human NoV remains a mystery. When intestinal biopsy of human volunteers 
infected with GI.1 and GII.1 NoV were evaluated by immune-electron microscopy (IEM), viral particles 
were not detected (Dolin et al., 1975; Agus et al., 1973). This lead to the assumption that human NoV 
infects a small number of cells in vivo. The attempts to develop a cell culture system to grow NoVs has 
proven to be  unsuccessful as they could not be cultured (Duizer et al., 2004). However, recent advances 
with animal models suggest that several cell types including dendritic cells (DC), macrophages (Mᵩs) 
and enterocytes support the in vivo replication of NoV at low levels (Karst, 2010) .  
Histo-group blood antigens (HBGAs) are carbohydrates linked by proteins or lipids in the surface of 
mucosal epithelial cells that are recognized by human NoV (Tan & Jiang, 2005) . The 
glycosyltransferases that control HBGAs synthesis are encoded by the Lewis (FUT3) and Secretor 
(FUT2) gene families (Bucardo et al., 2008). The association between NoVs and HBGAs has been 
proven to be essential for NoV strains (Karst, 2010). HBGAs are used as receptors by NoV and NoVs 
have adapted themselves into using different types of HBGA. 80% of the population are individuals 
with wild type FUT 2 gene which susceptible to Norwalk-virus infection and are referred to as secretors, 
while 20% of the population have a null FUT 2 gene which is completely resistance to Norwalk-virus 
infection and are referred to as non-secretors (Lindesmith et al., 2008) . Tan and colleagues  described 
that the NoV strains had distinct binding profiles, this suggesting that strains can be differentiated into 
those that binds Lewis epitope or those that binds A or B epitope (Tan et al., 2009). GI and GII have 
genogroup specific differences in there receptor binding interface of the capsid that interacts with the 
HBGAs, therefore even if both genogroups interact with the same HBGAs, the specific residues in the 
binding will be different (Karst, 2010). The high prevalent GII.4 NoV strains that were circulating in 
the 1970s to the 1980s all displayed a similar HBGAs binding pattern (B antigen, LewisY and H type 
3), a strain circulating in 1997 used the same HBGAs profile with a strain that was circulating in 2006 
along with A and LewisB antigen (Cannon et al., 2009). Strains isolated from a 2002 outbreak were 
unique from strains isolated from outbreaks in 2004 and 2005, they failed to bind to HBGAs suggesting 
that they bind to other carbohydrates (Bok et al., 2009; Lindesmith et al., 2008). 
  
Although NoV strains show a distinct HBGAs binding pattern, they can all infect almost everyone 
because of their high genetic variation (Le Pendu et al., 2006). This showing the likelihood of human 
NoV to co-evolve together with their human host (Karst, 2010). The association with HBGAs is 
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important for in vivo infection even though cell lines expressing HBGAs in vitro are resistant to 
infection and transfection of the FUT 2 gene does not promote infection (Duizer et al., 2004; Guix et 
al., 2007). It is suggested that cells expressing HBGAs are not the intended target of NoV infection, 
and that the binding to HBGAs that are found on the surface of enterocytes may facilitate the attachment 
of NoV to the intestinal wall while the binding of NoV to other neighbouring cells like dendritic cells 
and macrophages may be essential for the entry and replication of the virus (Karst, 2010). 
 
1.2.4 Epidemiology 
NoV affect individuals of all age groups but the highest rate of gastroenteritis is among young children 
(Lopman, 2015). The estimated incidence NoV for all age groups is mostly available in developed 
countries. With a  life expectancy of 80 years, an average person will experience 3 to 8 episodes of NoV 
illness in their lifetime, of which one of them will occur before age 5 (Phillips et al., 2010). The 
incidence of NoV infection is 5 times higher in children under 5 years compared to the rest of the 
population (Phillips et al., 2010). The incidence of disease across all age groups in low income countries 
is not well documented. Therefore, comparing age specific incidence is difficult between those 
countries. A study in Peru demonstrated the incidence of NoV to be 50 per 100 person years in the first 
two years (Saito et al., 2014), with the highest incidence in children between 6 – 23 months suggesting 
that children between 0 – 5 months are protected by maternal antibodies (Lopman, 2015). Other studies, 
in Kenya and Guatemala estimated the incidence of NoV to be 10 times higher in children 5 years and 
below compared to children older than 5 years (Lopman, 2015). Generally, the incidence of 
gastroenteritis caused by NoV is highest in the age group 6 – 23 month (Shioda et al., 2015). Nearly all 
children are infected at least once by 5 years of age (Son et al., 2013; Menon et al., 2013; Nurminen et 
al., 2011) and multiple infections are a result of short lived immunity and no cross protection to the 
diverse strains of NoV. Substantial progress in understanding the diversity and evolution of NoV 
gastroenteritis has been made in the past decades (Eden et al., 2014; Eden et al., 2013; Siebenga et al., 
2009). Developed countries like the United States and the European countries have implemented 
surveillance systems that resulted in an increase in NoV data and diversity while African continents 
only exhibit a few NoV surveillance studies (Mans et al., 2016). Those southern African studies 
demonstrated a mean overall prevalence of 13.5 % (range 0.8– 25.5 %) for NoV infection in young 
children. More recently, and reports from other parts of Africa identified similar prevalence’s of NoV 
infection (Smit et al., 1999; Taylor et al., 1996; Mans et al., 2016). 
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1.2.4.1 Globally 
NoV is responsible for almost 50 % of all non-bacterial gastroenteritis outbreaks and 18 % of all 
gastroenteritis cases worldwide (Patel et al., 2009). This figure is skewed due to the scarcity of 
surveillance data from under developed countries. The estimated annual cost of Norovirus related health 
care is about 777 million US dollars in the USA alone. In 2009 and 2010, NoV was responsible for 14 
000 hospitalizations, 281 000 emergency visits, and 627 000 outpatient visits in the USA, representing 
$273 million of direct health costs for each of the 2 years, nationwide, for children aged 5 years and 
below (Payne et al., 2013).  Australia is estimated to have 1.8 million cases of NoV infection each year 
(Hall et al., 2005). In 2002 to 2008, more than 700 000 cases of NoV infection were reported in 
Germany and 26 % of those cases resulted in hospitalization (Belliot et al., 2014). In England, NoV 
was responsible for 9 % of gastroenteritis related hospitalization which increased to 19 % when elderly 
were included (Haustein et al., 2009). England estimated the annual loss of $184 million due to 
nosocomial gastroenteritis outbreaks conducted from a survey in 1999 and a large part was caused by 
NoV infection (Lopman et al., 2004). Studies in England and Wales suggested death associated with 
NoV infection of individuals older than 65 years might reach 20 % (Belliot et al., 2014). Many countries 
have not studied the prevalence of NoV in sufficient detail to gain reliable burden estimates. There is 
scarcity of data from Africa where the effect of gastroenteritis probably has more severe consequences 
(Desselberger & Goodfellow, 2014). Therefore, additional high-quality studies in these settings is 
crucial to improve disease estimates.  
 
1.2.4.2 Africa 
The greatest burden of diarrheal disease occurs in developing countries, with up to 200 000 deaths each 
year in children less than 5 years of age alone (Patel et al., 2008). In 1996 and 1999 Southern African 
countries like Angola, Zimbabwe, Namibia and Mozambique published reports on the high prevalence 
of IgG antibodies GI.1 (Atmar et al., 2008). South Africa (SA) first encountered NoV associated 
gastroenteritis in 1993 where genogroups GI.1 (Hawaii strain) and GII.1 (Norwalk strain) were 
identified as the causative agents in outbreaks (Taylor et al., 1993). In 1996, a study in Pretoria 
investigated the effect of Norwalk virus infection in young children and adults up to the age of 40 years. 
They reported that 57 % of the population was exposed to NoV between age 1 – 2 years (Taylor et al., 
1996). In 1997, the estimated prevalence for human calicivirus was 3.3 % with NoV signifying 89 % 
and 11% for sapoviruses (Wolfaardt et al., 1997) NoV GI and GII were both identified but GII was the 
most dominant. Another study was reported in both urban and rural population of SA where antibody 
prevalence levels ranged between 94 – 96 % (Smit et al., 1999). NoV was also characterized in the year 
2008 in hospitalized paediatric patients with acute gastroenteritis in a Pretoria hospital where the strain 
of GII.4 was first reported in SA (Janet et al., 2010). SA has no mandatory gastroenteritis outbreak 
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reporting system and therefore, outbreaks of NoV remain underreported and the prevalence of infection 
underestimated. 
 
1.2.5 Norovirus Seasonality in Africa 
In Africa, NoV seasonality is not well understood compared to the northern hemisphere (Mans et al., 
2016). North African countries experienced NoV infection in different months. In Morocco and Libya, 
NoV peaked in June to September (summer months), Egypt NoV peaked in October to May (cold 
months) while NoV infection in Tunisia no clear seasonal pattern was observed (El Qazoui et al., 2014; 
Abugalia et al., 2011; Benmessaoud et al., 2015; Rackoff et al., 2013; Sdiri-Loulizi et al., 2009; 
Hassine-Zaafrane et al., 2013). In West Africa, Nigeria experienced NoV infections in October (rainy 
month) while in Ghana and Burkina Faso NoV peaked in December to April (cool dry months) 
(Nordgren et al., 2013; Armah et al., 2006; Krumkamp et al., 2015; Oluwatoyin  et al., 2012). In East 
Africa, only a study in Tanzania described seasonality of NoV, which was detected in April, at the end 
of the rainy season (Moyo et al., 2014). In Southern Africa, Malawi experienced NoV at end of rainy 
months and in South Africa NoV peaked in September to November (Dove et al., 2005; Trainor et al., 
2013; Mans et al., 2010). Ghana and Egypt NoV seasonality NoV was the same as for Rotavirus both 
falling in cool, dry months. The peak of NoV and Rotavirus did not overlap for other African countries. 
Climate change in Africa can be divided into wet and dry seasons with North and Southern Africa 
experiencing four seasons. NoV seasonality can be influenced by many factors, these include humidity, 
temperature, rainfall and human behaviour (Mans et al., 2016). Studies have shown the murine NoV 
favours low humidity for its survival (Colas de la Noue et al., 2014). Most African countries experience 
a peak NoV activity in cold and dry months of the year. This might be associated with improved virus 
survival in low humidity environments. Cultural behaviour and population densities may also be a 
reason for different seasonality that is experienced across the African continent (Colas de la Noue et 
al., 2014). 
 
1.2.6 Molecular Epidemiology 
Although 32 genotypes have been identified within human NoV (Kroneman et al., 2013), GII.4 is still 
the genotype frequently associated with gastroenteritis pandemics and it accounts for more than 80 % 
of all human NoV infections (Siebenga et al., 2009; Tu et al., 2008). Because human NoV could not be 
cultured, its evolution remains unknown and it is difficult to explain why GII.4 viruses are successful 
(White, 2014). and is currently still in research (Siebenga et al., 2009). GII.4 is responsible for 6 major 
pandemic outbreaks that occurred in the last 2 decades. These pandemic include the US 96 that occurred 
in the 1990s (Noel et al., 1999; White et al., 2002), Farmington Hills – 2002 (Lopman et al., 2004; 
Widdowson et al., 2004), Hunter – 2004 (Bull et al., 2006), Den Haag – 2006b (Tu et al., 2008; Eden 
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et al., 2010), New Orleans – 2009 (Yen et al., 2011) and the most recent Sydney – 2012 (Eden et al., 
2014). The first four pandemics are thought to have occurred due to mutation in the P domain that 
resulted due to an  antigenic drift from the previous GII.4 viruses (Bull et al., 2010; Debbink et al., 
2012; Donaldson et al., 2010). Nonetheless, the recent two cities, New Orleans – 2009 and Sydney – 
2012 both show the intra-genotype recombination where ORF1 and ORF2 overlaps and they have 
evolved through a process of antigenic shift and antigenic drift (Eden et al., 2013). The emerging of 
GII.4 corresponded with the sharp increase of gastroenteritis epidemics and Norovirus infections 
globally. This was shown by the Sydney – 2012 GII.4 pandemic which was first identified in Australia 
in March 2012 (Bull et al., 2010), by August 2012, it was responsible for 25 % of acute gastroenteritis 
associated with NoV (Eden et al., 2014). By November 2012 to January 2013, it had replaced most of 
GII.4 NoV resulting in an increase in the number of gastroenteritis outbreaks across the world. Currently 
Sydney – 2012 is the most prevalent NoV, although looking at past evolutional patterns of GII.4, it is 
expected that in a couple years to come, it will be replaced by a new GII.4 variant (White, 2014). GII.3 
also causes sporadic infection in young children (Liu et al., 2014). It was dominant in various countries 
in the late 1970 – 1980s and early 1990s.  GII.17, infection of pigs, dogs, cattle and macaques emerged 
during 2014 – 2015 epidemic in China and South-east Asia, causing major epidemic of gastroenteritis 
(Huang et al., 2017). 
 
1.2.7 Norovirus in different age groups 
       1.2.7.1 Children 
Children aged 5 years and below have the highest incidence of NoV gastroenteritis. The incidence of 
disease is between 15 900 to 27 700 per 100 000 population in children <5 years and this is 6,5 times 
the incidence of children ≥ 5 years (Phillips et al., 2010).  Children in this age group have shown higher 
rates of NoV associated with outpatient’s visits, hospitalization and emergency department visits. In  
USA where RoV vaccine is widely used (Payne et al., 2013), NoV is now the leading cause of 
gastroenteritis in children 5 years and below but data from developing countries is still lacking (Belliot 
et al., 2014). NoV is associated with 18 % all diarrheal disease worldwide in children 5 years and below 
and NoV has been detected in stool of diarrhoea-free children which makes it difficult to know the 
correct burden of disease in children from developing countries (Kotloff et al., 2013; Lopman et al., 
2014). 
       1.2.7.2 Adults 
People 65 years and older suffer more from NoV infection than younger adults. With more than 800 
deaths per year in USA alone, the mortality ratio in this age group is 20 times higher than the mortality 
of people aged 18 – 64 years of age (Verhoef et al., 2013; Desai et al., 2012). Elderly people in general 
do not have a higher risk of infection. Those individuals living in old-age homes and other care facilities 
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that have a higher risk of being affected during outbreaks (Wikswo & Hall 2012; Kroneman et al., 
2008).  These outbreaks are caused by GII.4 virus which appears to result in more severe outcome 
compared to other genogroups and causes hospitalization and death (Desai et al., 2012). There is 
increasing evidence that NoV outbreaks in nursing homes causes excess mortality (Trivedi et al., 2012). 
 
1.2.8 Clinical features and Treatment 
NoV symptoms are described based on reports from gastroenteritis outbreaks and human volunteer 
studies (Moreno-Espinosa et al., 2014). The clinical presentation includes diarrhoea, vomiting, nausea, 
fever, chills, myalgia and abdominal cramps. Diarrhoea and vomiting are the predominant symptoms 
of NoV infection, being present in 90 % and 75 % of cases respectively (Rockx et al., 2002). Adults 
normally experience diarrhoea as the predominant symptom while young children experience nausea 
and vomiting more than diarrhoea. NoV diarrhoea is characterised by the passage of loose or watery 
stool without blood or mucus at least three time a day (Mans et al., 2016). Nausea and vomiting result 
from the brief gastroparesis that occurs after viral infection and is resolved when the illness resolves 
itself in 12 – 72 hours (Meeroff et al., 1980). NoV infections are mostly self-limiting and most patients 
recover without becoming debilitating and life-threatening. Young children and elderly people are at 
risk of dehydration. This can lead to electrolyte disturbance which can result in hospitalization or death 
if not treated (Lopman et al., 2003). Patients become resistant to re-infection only for 4 – 6 months, as 
there is no development of long term immunity. Studies involving human volunteers revealed that 
infection starts in the small bowel where there is expansion of the villi and shortening of the microvilli 
(Wilhelmi et al. 2003). Nearly 30% of NoV infections are asymptomatic. People with asymptomatic 
infection have a similar viral load and shedding duration as symptomatic individuals (Rockx et al., 
2002) 
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1.2.9 Transmission           
 
Figure 3:  Transmission of Human NoV particles (Moreno-Espinosa et al., 2004) 
 
NoVs are highly transmissible and humans are the only known reservoir for human NoV (Fields, 2007). 
NoV can be transmitted through a variety of routes (Fig 1) but mainly through person to person contact 
(faecal-oral routes), aerosolized vomit and contaminated surfaces (Ester et al., 2004). Aerosolized vomit 
that contains NoV can be swallowed and inhaled but there is no evidence that the virus replicates in the 
respiratory tract (Marks et al., 2003; Marks et al., 2000). NoV can also be transmitted through ingestion 
of contaminated food, especially oysters and shellfish, and drinking contaminated water (Parashar et 
al., 1998; White et al., 1986) .  
NoV have a low infectious dose of  ~18 viral particles coupled with high viral concentration in the 
stools during shedding with 10 to 100 viral copies per gram of faeces even in asymptomatic infections 
(Teunis et al., 2008; Aoki et al., 2010). Thus suggesting, that up to 5 billion infectious doses can be 
shed by an individual in one gram of faeces (Hall et al., 2012). Prolonged shedding of the virus increases 
the risk of transmission and is of concern in food handlers and health care workers even after symptoms 
are resolved (Parashar et al., 1998). NoV are environmentally stable and have the ability to survive in 
both freezing and extremely hot temperature. They are resistant to most commonly used chemical 
disinfectants, like high levels of chlorine and can survive on surfaces for up to two weeks (Lopman et 
al., 2012). This make it challenging to eliminate NoV from contaminated water (Barker et al., 2004).  
The most common settings for NoV outbreaks are closed and semi closed communities. This includes 
a variety of institutions, cruise ships, schools, day care centres, nursing homes, hospitals and restaurants 
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(Centers for Disease Control and Prevention (CDC), 2002). The size of reported outbreaks ranges from 
less than 10 individuals to epidemics of more than 6000 people (Fankhauser et al., 1998). Duration of 
outbreaks ranges from 24 hours to 139 days with a median of 8 days (Lopman et al., 2003).  
Water-borne outbreaks have been reported involving drinking water, swimming pools, lake water, well 
water and ice (Blevins et al., 2004; Lawson et al., 1991). These outbreaks also occur when sewage 
contaminates water that is supplied for drinking purposes are accidently consumed during recreational 
activities. Foreign travelling can also be a risk factor for NoV transmission, with high risk possible 
resulting from the change in behaviour while traveling and being exposed to different strains of NoV 
(Chang et al., 2006; Chang et al., 2004). 
 
1.2.10 Laboratory Diagnosis and Detection Methods 
In 1972, NoV was first detected in stool using Immuno-Electron Microscopy (IEM). This method is 
labour intensive, has low sensitivity and requires highly skilled personnel (Lopman, 2015). In the 90’s, 
Norwalk virus and Southampton virus, prototype of NoV were cloned and sequenced. This opened the 
way for detecting NoV directly from stool samples based on RT-PCR (Jiang et al., 1992; De Leon et 
al., 1992).  
Similarly, NoVs have been used in cloning technology, expression of virus like particles (VLPs) and 
viral protein. This has led to the advancement of serological assays with antigens that may be used in 
the production of monoclonal antibodies and polyclonal sera (Jiang et al., 1992). This led to the 
development of immune-chromatography and antigen capture enzyme immunoassay tests that are 
available commercially (Lopman, 2015). However, regardless of the antigenic and genetic variation and 
viable viral loads in NoV stool specimens, the tests have low sensitivity and may not capture the full 
range of circulating viruses (Bruggink et al., 2013; Gray et al., 2007). Thus, enzyme immunoassays and 
other antigen detection tests may only become useful in outbreak settings (Gray et al., 2007; Kirby et 
al., 2010; Morillo et al., 2011; Derrington et al., 2009; Bruins et al., 2010).  
There are many commercial EIA for NoV stool detection methods, their sensitivity and specificity 
depend on the diagnostic goal: clinical diagnosis versus outbreak investigation (Jiang et al., 1992).  
Generally, EIA are highly specific for the detection of NoVs but generally not sensitive enough to detect 
a wide range of NoVs (Jiang et al., 1992) . Newer EIAs have been developed based on antibodies 
against a wide range of viral antigens but sensitivity remains restricted (de Bruin et al., 2006). Their 
high specificity makes them useful for diagnosing NoV in outbreaks investigation, when there are many 
specimens available and confident detection in few cases might be adequate for confirming the cause 
of disease (de Bruin et al., 2006; Gray et al., 2007).  However, sensitivity of such assays are genotype 
dependent and results differ based on the diversity of the circulating strain in the population (de Bruin 
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et al., 2006; Gray et al., 2007). As a result, samples that are negative by EIA in outbreaks should be 
further tested using real-time RT-PCR. With further enhancement of these assays to improve their 
sensitivity, they could be useful in rapid diagnosis of NoV in sporadic diarrheal cases (Patel et al., 
2008). 
Real-time PCR using TaqMan assays is currently the most widely used method for the detection of 
NoV. It is highly sensitive and can detect low viral load present in an asymptomatic individual or a 
person that recovered within a few weeks from NoV gastroenteritis. The high sensitivity allows small 
amounts of virus to be detected in the samples of asymptomatic individuals and people that have 
recently recovered from NoV from infection (Lopman, 2015). Although inaccurate detection is a cause 
for concern in most assays, it is more problematic in Real-time PCR as it can detect as low copies 
number possibly non replicating virus (Lopman, 2015). In each of the NoV genogroups, the ORF1 – 
ORF2 junction is the most conserved region in the Norovirus genome, making it the main target for 
primers and probes for nucleic acid detection and amplification (Lopman, 2015). 
Recently, many platforms that can simultaneously detect a wide range of pathogens have been 
developed for the detection of parasites, bacteria and viruses. These platforms include Luminex and 
BioFire which can detect all the pathogens and still differentiate between GI and GII NoV. With these 
diagnostics, understanding the cause of illness will be challenging if multiple pathogens are detected in 
the stool of an individual person (Lopman, 2015). 
 
1.2.11 Immunity and Vaccine 
The immunity of human NoV is not well understood which hampers the strategies for the formulation 
of immunization against NoV (Estes et al., 2000). The failure to cultivate NoV in cell culture until 
recently prevented researchers from studying the role of neutralizing antibodies (Fields, 2007). 
Recombinant VLPs expressed in transgenic plants or in Baculovirus have been shown to be 
immunogenic when administered to human volunteers. This raises the possibility for protection through 
vaccination (Ball et al., 1999). These vaccines could be useful to those who are at high risk of severe 
disease, including elders in nursing homes, young children in day care centres and 
immunocompromised individuals. Nonetheless, there are still many challenges in the development of 
NoV vaccine, including the lack of long term immunity, understanding of immune correlates and the 
protective cross-immunity against all the multiple existing genetic viruses (Tacket et al., 2003) .   
Although NoV vaccine is still under development (Atmar and Mullen, 2013), it will take years before 
a licensed vaccine will be available (Debbink et al., 2014). The protective immune correlate is not 
understood but it is assumed that the adaptive immune system, antibodies along with CD4 and CD8 
lymphocytes are essential for protection against NoV infections (Tomov et al., 2013; Fang et al., 2013) 
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. The vaccine may be of limited use in immunocompromised patients with weakened B – cell and T – 
cell function except for patients that are suitable for the incorporation of NoV vaccine “when available” 
with other recommended vaccines before or after organ or stem cell transplantation (Danziger-Isakov 
and Kumar, 2013). An effective NoV vaccine that will lower the overall prevalence of disease in the 
general population and in health care workers will benefit immunocompromised patients indirectly by 
limiting their exposure to the disease, thus preventing infection (Eden et al., 2014).  
 
1.2.12 Prevention and Control 
Infection control is still the first line of defence against the spread of NoV infection (MacCannell et al., 
2011), and it is more important in immunocompromised individuals (Atmar and Mullen, 2013). No 
specific medication to treat NoV infection and therefore it cannot be treated with antibiotics. Drinking 
lot of liquids to replace fluids from vomiting and diarrhoea also oral rehydration fluids ((UK), 2009). 
Hospitals and long term care facilities should adhere strictly to infection prevention practices when 
caring for immunocompromised patients to limit exposure of patients, staff and visitors to NoV (Dew 
et al., 2005). The US centre of disease control and prevention (CDC, 2002) issued guidelines for the 
prevention of NoV infections, effective disinfectants and managing healthcare settings (Lopman, 2015). 
The restriction of movements between patients and staff, attention when washing hands and improved 
environmental cleaning has led to positive outcomes in nosocomial settings. Some NoV outbreaks were 
linked with health care workers handling immunocompromised patients while sick (Doshi et al., 2013). 
 NoVs are generally resistant to ethanol based cleaning solutions and detergents therefore require 
additional chemical disinfectants (Barker et al., 2004; Duizer et al., 2004). Effective disinfectants are 
those containing hypochlorite, phenolic based and hydrogen peroxide based formulations (Barker et al., 
2004; Doultree et al., 1999). Special care must also be given when processing food in regards to the 
frequent occurrence of foodborne outbreaks (Koopmans and Duizer, 2004). Recent studies have shown 
that depuration of oysters does not completely remove NoV as they bind to oyster tissues using 
carbohydrates structure similar to that of a human histo-blood group antigen (Le Guyader et al., 2006).  
Therefore, precaution must be taken to prevent oysters from being contaminated by faeces and vomit 
or any treatment plant effluent. Increased purification of drinking and swimming water can also help 
decrease the incidence of NoV outbreaks (Lodder et al., 1999). 
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CHAPTER 2 
 
METHODOLOGY 
 
2.1 Ethics Approval 
Ethics approval for this study was issued by the University of KwaZulu-Natal’s Biomedical Research 
Ethics Committee (BREC), reference number BE350/15 (Sub-study of BE222/13). Caregivers of the 
participants provided written informed consent prior to initiation of study procedures.  
2.2 Study Area and Population 
The study was conducted at King Edward VIII Hospital situated at Ward 33 in eThekwini District of 
KwaZulu-Natal (KZN), South Africa. It is one of the largest hospitals in the southern hemisphere, 
providing regional and tertiary services to the whole of KZN and Eastern Cape. Children enrolled in 
this study were 5 years of age and below presenting with acute diarrheal disease at the paediatric 
outpatient department. Those eligible were admitted for in-patient care. 
 
2.3 Study design 
The study questionnaire was developed and designed by the Medical Microbiology department of the 
University of KwaZulu-Natal (UKZN). The questionnaire was designed in both English and IsiZulu, 
and outlined the importance of the study as well as questions regarding risk factors associated with 
diarrhoeal disease, medical history, clinical symptoms and demographic information. In June 2014, the 
specimen collection phase of the study began with hospitalized patients at the paediatric ward of King 
Edward VIII Hospital. The objective and concept of this study were clearly explained to the caregiver 
of each potential participant. Confidentiality was ensured by giving each patient a number. The consent 
forms were the only documents containing the identities of the participants and they were kept safe in 
a separate location. 
 
2.4 Specimen Collection and Preservation  
After written informed consent was obtained from the parent/guardian, stool specimens were collected 
by trained personnel from soiled diapers using an autoclaved wooden spatula. The specimens were 
transported in a 10 ml screw capped tube and transported at 2 – 8 oC in a cooler box with ice packs to 
the Medical Microbiology laboratory. Specimens were preserved by aliquoting 0.1 g of stool into 2 ml 
microcentrifuge tubes and stored at – 80 oC until further use. 
. 
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2.5 Enzyme Immunosorbent assay (ELISA) 
The IDEIA™ Norovirus kit (Oxoid Limited, Basingstoke Hampshire, United Kingdom) was used to 
detect norovirus (NoV). It is a single plate with micro-wells pre-coated with monoclonal antibodies for 
both GI and GII NoV strains. The assay is a sandwich ELISA (figure 1) and was carried out according 
to the manufacturer’s instructions. Briefly, 1 ml of sample diluent was added to 0.1 g of stool to make 
a 10% stool suspension. The suspension was then vortexed, incubated at room temperature for 10 
minutes and centrifuged for 5 minutes at 5000 rpm. An amount of 100 µl of each stool supernatant 
as well as of the negative and positive control (provided with the kit.) were added to separate micro-
wells. This was followed by the addition 100 l of conjugate to all micro-wells. This conjugate consisted 
of peroxidase labelled polyclonal antibodies and monoclonal antibodies against NoV GI and GII in a 
buffered protein solution containing antimicrobial agent labelled with a blue dye. The content of the 
wells was mixed gently and then incubated at 30 oC for 60 minutes. Unbound antibodies were removed 
from the micro-wells by washing 5 times with 350 µl of Tris-buffered saline. After the last wash, the 
plate was turned upside down on an absorbent paper to remove all traces of buffer and 100 l of the 3, 
3’, 5, 5’-tetramethylbenzidine (substrate) was added to all wells and incubated at 30 oC for 30 minutes. 
The reaction was stopped by adding 100 l of sulphuric acid (stop solution) before reading the results. 
The presence of bound antibodies were indicated by the colour change which was triggered by 3,3’,5,5’-
tetramethylbenzidine (TMB), a visualizing agent that act as a hydrogen donor for the reduction of 
hydrogen peroxide to water by horseradish peroxidase enzyme. The resulting di-imine caused the 
solution to take on a blue colour. The optical density (OD) readings were measured at a wavelength of 
450 nm. The cut-off value was calculated as 0.10 plus the OD value for the negative control. Samples 
with OD values greater than the cut-off value plus 0.01 were regarded as positive, and samples with 
OD values lower than the cut-off value minus 0.01 were regarded as negative. 
. 
 
Figure 4: Sand-witch ELISA 
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2.6 Ribonucleic acid (RNA) extraction 
RNA extraction was performed using the QIAamp® viral RNA Mini-kit (Qiagen, Valencia, CA, and 
USA) according to the manufacturer’s instructions. One ml of PBS, pH 7.2, was added to 0.1 g of stool 
to make a 10 % stool suspension. The suspension was then briefly vortexed and centrifuged at 14000 x 
g for 1 minute. The volume of lysis buffer and -carrier RNA mix needed per batch of sample was 
calculated by the number of samples to be simultaneously processed using the following formula: -  
N x 0, 56 mL = Y mL and Y mL x 10 µL/mL = Z µL. 
 
N: number of samples to be processed, Y: volume of buffer AVL, Z: volume of carrier RNA-elution 
buffer.  
 
Of the buffer AVL-carrier RNA-buffer mix 560 µL was pipetted into a 1.5 mL microcentrifuge tube 
followed by the addition of 140 µL of the 10 % stool suspension. The sample mixture was mixed by 
vortexing for 15 seconds and incubated at room temperature for 10 minutes. The sample mixture was 
centrifuged briefly for 30 seconds at 14000 x g, then 560 µL of molecular grade ethanol (98 %) was 
added followed by vortexing. The tubes were centrifuged, then 630 µL of the lysate was dispensed into 
the QIAamp spin mini column connected to a 2 mL collection tube and centrifuged at 6000 x g for 1 
min. The spin mini column was then placed into a new 2 mL collection tube and the tube containing 
the filtrate was discarded. This procedure was repeated twice to filter out all the remaining volume of 
the lysate. Afterwards, 500 µL of wash buffer (AW1) was added to the spin mini column and centrifuged 
at 6000 x g for 1 min. The spin mini column was then placed into a new 2 ml collection tube and the 
tube containing the filtrate was discarded. Then, 500 µL of a second wash buffer (AW2) was added to 
the spin mini column followed by centrifugation at 14,600 x g for 3 min. Next, the spin mini column 
was placed into a new collection tube and centrifuged at full speed for 1 min to remove residual wash 
buffers. The spin mini column was then placed into a 1.5 ml microcentrifuge tube and 60 µl of buffer 
AVE was added to the spin mini column which was left to equilibrate at room temperature for 1 min. 
The RNA was eluted by centrifugation at 6000 x g for 1 min. The RNA samples were stored at – 80 oC 
until further use. 
 
 
2.7 Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR) 
Real time RT-qPCR was performed using the one-step RealStar® Norovirus RT-PCR kit (Altona 
diagnostic, Hamburg, Germany) according to the manufacturer’s instruction. Briefly, 5 µL of each viral 
RNA or controls (positive and negative controls) was used as a template. A master-mix reaction of 20 
µL containing 5 µL of Master A, 15 µL of Master B and 0.5 µL of the internal control. Master A and B 
contained buffer, enzyme, and primers for both genogroups and probes. After the master-mix 
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preparation, a PCR reaction of 25 µlLwas added to a 96 well reaction plate, the plates were covered 
with adhesive film cover and centrifuged at 1000 x g for 30 seconds. Amplification of NoV GI and GII 
were performed using an Applied Biosystems® 7500 Real-Time PCR Systems (Applied Biosystems™, 
USA). The reverse transcription reaction at 50 oC for 10 minutes was followed by denaturation at 95 oC 
for 10 minutes and amplification at 95 oC for 15 seconds and 95 oC for 45 seconds in 45 cycles. The 
positive and negative controls were used to ascertain integrity of the reaction. Samples were regarded 
positive when amplification occurred 
 
2.8 Statistical analysis 
The sample size was calculated using the prevalence formulae by Hajian-Tilaki (2014). Assuming 
Norovirus prevalence of 20 % and an ELISA sensitivity of 72.8 %. An estimated 280 stool samples or 
more were needed for the Norovirus prevalence study at 95 % confidence interval. MedCalc version 
12.2.1 (MedCalc Software, Mariakerke, Belgium) was used to determine sensitivity, specificity and a 
95 % confidence interval of the ELISA tests compared to the RT-qPCR assays. Data was analysed using 
SPSS 22. Categorical variables were compared using Chi-square test. A p-value less than 0.05 was 
considered to be statistically significant. 
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CHAPTER 3 
 
3. RESULTS 
 
3.1 ELISA versus RT-qPCR 
A total of 182 stool specimens were tested for the presence of NoV using two different testing 
methods, the antigen detection (ELISA) and RT-qPCR. Nineteen of 182 (10.5 %) tested positive with 
ELISA and 41/182 (22.5 %) tested positive with RT-qPCR. When the two methods were compared, 
RT-qPCR detected 31/182 (17 %) more positives then ELISA and 9/182 (5 %) of the ELISA positives 
were negative when tested by RT-qPCR. The RT-qPCR did not only detect NoV, it was also able to 
differentiate between GI and GII, which causes the most NoV outbreaks in human. All positives in 
this study were GII (100 %).  
 
 
 
Figure 5: Detection of Norovirus using two different methods 
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Table 1: Comparison of the antigen detection test and RT-qPCR detection methods  
 
ELISA Results       RT-qPCR Results    No. of Specimens 
 Positive Negative  
Positive 10 (5.5 %) 9 (5.0 %) 19 (10.5 %) 
Negative 31 (17.0 %) 132 (72.5%) 163 (89.5 %) 
No. of Specimens 41 (22.5 %) 141 (77.5%) 182 (100 %) 
    
 
Sensitivity and Specificity 
MedCalc version 12.2.1 (MedCalc Software, Maria-kerke, Belgium) was used to determine sensitivity, 
specificity and 95 % confidence intervals of the ELISA tests compared to the RT-PCR assays. This 
resulting in a sensitivity of 24 % (95 % Cl = 12 % - 40 %) and a specificity of 94 % (95 % Cl = 88 % - 
97 %). The positive predictive value (PPV) was 53 % (95 % Cl = 29 % - 76 %) and the negative 
predictive value (NPV) was 81 % (95 % Cl = 74 % - 87 %). 
 
 
3.2 Sociodemographic and clinical features 
Table 2 shows a comparison of sociodemographic and clinical characteristics between NoV positive 
and negative cases. Ninety-three females (51 %) and eighty-nine males (49 %) were recruited. Of the 
41 specimens that tested positive for NoV, 18/41 (44 %) were females and 23/41 (56 %) were males (p 
= 0.3). in the age group stratified analysis, the NoV prevalence was different between the age groups 
but not statistical significant (p = 0.6). the highest prevalence was observed in the age group 12 - 23 
months (39%). This was followed by ≤ 5 months and 6 – 11 months age group, both with a prevalence 
of (26.8 %). This is in line with what has been found in previous studies as children older than 2 years 
may have developed immunity due to previous NoV infection as it is suggested that a child will 
experience at least one NoV infection before the age of 5 years. The distribution of NoV infection was 
not statistical significant (p = 0.8). Six (14.6 %) of the NoV positive cases were HIV positive, 20 (49 
%) were HIV negative, nine (22 %) were HIV exposed and six (14.6 %) were unknown as records of 
their HIV status could not be found. 
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Table 2: Sociodemographic and clinical features of NoV positive compared to NoV negative 
children   
 
 
 
 
  
 
NoV positive 
(n = 41) 
NoV negative 
(n = 141) p value 
Sex (n=182)  
 
 
Female 18 75 0.3 
Male 23 66  
Age group (n=182)  
 
 
≤ 5 months 11  51 0.6 
6 - 11 months  11 35  
12 - 23 months 16  39  
 24 - 35 months 2 11  
 36 - 60 months 1  5  
HIV status (n=182)  
 
 
positive 6  18 0.8 
negative 20 81  
exposed 9  26  
unknown 6  16  
Duration of Diarrhoea 
(n=182)  
 
 
1 - 3 days 18 74 0.4 
4 - 5 days  15  34  
≥ 6 days 6  28  
unknown 2  5  
Fever (n=182)  
 
 
> 38.5 ⁰C 7  15 0.2 
≤ 38,5⁰C 33  126  
unknown 1  0  
BMI (n=182)  
 
 
Underweight (< 18.5) 33 112 0.6 
Healthy weight (18.5 - 
24.9) 6  
16 
 
Overweight (25 - 29.9) 0 1  
Obese (> 30) 0 4  
unknown 2  8  
Mode of Feeding (n=89)  
 
 
Breast feeding 7  33 0.5 
Mixed feeding 6 43  
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CHAPTER 4 
 
4. DISCUSSION 
In the province of KwaZulu-Natal (KZN), South Africa, there is a discrepancy between the level of 
vaccination coverage and infant mortality (van den Heever, 2012). The two major syndromes of 
infectious diseases that contribute to high mortality rate are lower respiratory tract infections and 
diarrhoea. In an attempt to uncover the reason for that discrepancy for diarrhoea, this study investigated 
the prevalence and detection of human NoV in children 5 years and under in a tertiary hospital in KZN, 
(King Edward VIII hospital) between June 2014 and August 2015.  
The result of the study provided important insights into the burden of disease caused by NoV as well as 
the epidemiological features of disease in KZN. The study was part of a bigger study where multiple 
investigators were looking at different aetiologies that also cause diarrhoea like RoV, Cryptosporidium 
parvum and Giardia lambliae. Bacterial aetiologies and additional viruses could not be included due to 
lack of funding.  
The NoV ELISA  test and NoV RT-qPCR kit were used to determine the prevalence of NoV infection 
in KZN (Figure 5). The comparison between the two assays allowed us to determine the most suitable 
test for routine diagnostic use. In total 50 of the 182 children tested NoV positive. The RT-qPCR assay 
was positive for 41 and the ELISA for 19 resulting in prevalence’s of 22.5 % and 10.5 % respectively 
(Figure 5). A study in Canakkale, Tukey also found similar result when they were detecting NoV using 
ELISA and RT-PCR. They found 16 (17.4 %) samples were positive for NoV, where 10/92 (10.9 %) 
samples were positive using ELISA and 15/88 (samples positive for real time RT-PCR (Aksu and Alper, 
2016). However, nine of the 19 ELISA positives could repeatedly not be confirmed with RT-qPCR. 
Spiking of these stools with PCR positive specimens showed that there was no inhibition (Table 1). It 
is therefore likely that these tests represented false positives or contained antigen in the absence of viral 
RNA. Page et al, reported on a study that was done in four site in South Africa where they detected 
NoV in 452/3103 (15 %) of hospitalized children <5 years with diarrhoea with the majority of disease 
in children <2 years 417/452 (92 %) (Page et al, 2017). The ELISA tests as screening test for NoV 
antigens was rapid and relatively easy to perform. However, the RT-qPCR assays with increased 
sensitivity could detect NoV RNA in an additional 31 (17 %) of patients (Table 1). The RT-qPCR also 
allowed determination of NoV genogroups. Most NoV detection tests target GI and GII as they are 
responsible for 90% of all human NoV infections. Therefore, GIV could have been missed in this study. 
Genogroup two (GII) was responsible for all the NoV infections during the study but we could not 
determine the specific genotype as genotyping could not be done due to lack of funding. A study in 
Turkey also detected majority of GII where they found 93 % GII and only one sample positive for GI 
by RT-qPCR (Aksu and Alper, 2016). Whilst ELISA tests are quick and easy to perform, they are less 
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sensitive compared to molecular methods. Molecular methods, on the other hand, are more expensive, 
have a longer turn around time and require more technical expertise than ELISA. Taking this into 
consideration, together with the high prevalence of NoV detected in this study, the ELISA test would 
provide rapid preliminary results in individual patients and could be used to establish the aetiology of 
community as well as nosocomial outbreaks. During outbreaks not all cases need to be diagnosed 
accurately. The increased sensitivity of the RT – qPCR assay could be utilized where NoV diagnosis is 
critical to patient care, as with immunocompromised patients, or in single cases of diarrhoea in non-
epidemic manifestations. A study by de Bruin and colleagues also compared the performance of the 
ELISA test to RT-PCR and found the sensitivity and specificity of ELISA to be low and propose RT-
PCR to be the gold standard for routine diagnosis of NoV in specimens from patients with gastroenteritis 
(de Bruin et al., 2006).  
Sociodemographic and clinical information were also recorded from the children enrolled in this study 
(Table 2). We found that there was no relationship between gender and infection as there was no 
statistical difference (p > 0.05) between the number of males 18/41 (44%) and females 23/41(56 %) 
with NoV infection. This is different from what was reported from a study done in Japan (Ozawa et al., 
2007), where they found males (10.8 %) to have a higher prevalence of NoV infection compared to 
females (6.4 %). In the present study, the highest rate of NoV infection was observed in children less 
than 24 months 38/41 (93 %). The peak detection rate occurred between 12 - 23 months which as was 
also shown in a French study (Tran et al., 2010). These findings indicate that the age of children was 
closely associated with the rate of NoV infections and that this peak might be due to poor patient hygiene 
and to frequent contact between young infants and other household and community members in a 
community with poor sanitation. Moreover, the weak immune systems of younger children might 
contribute to their higher susceptibility to NoVs than that of older children. Our findings confirm NoV 
infection usually occur in early childhood, which may indicate that protective immunity due to earlier 
infection is present after the age of 2 years (Sai et al., 2013). It also highlights the importance of 
implementing prevention strategies in the early years of life, although this might result in a shift in age 
category with the highest prevalence. Children older than 24 months had the lowest prevalence of NoV 
infection 3/41 (7.3 %). This suggest that older children may have protective immunity due to previous 
infection as studies have shown that a child will experience at least one NoV infection before age 5 
years.  
Infection with HIV is common among children of sub-Saharan Africa countries, and diarrhoeal disease 
is a leading cause of morbidity and mortality in HIV-infected children in these areas (Pavia et al., 1992; 
Thea et al., 1993). In this study, we found significantly lower incidence of NoV infection in HIV 
infected children compared to HIV uninfected cases. Only 24/182 (13 %) of all children enrolled in this 
study were HIV positive and from that six (25 %) were NoV infected. These findings differ from those 
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in a previous study (Cegielski et al., 1994), which reported a strong association between HIV infection 
and NoV infection. The lack of such an association in the current study can partly be explained by the 
fact that 6/41 (14 %) of our NoV positive patients had an unknown HIV status and 9/41 (22 %) were 
exposed to HIV by having an infected mother. Understanding the association between causative agents 
of diarrhoea in HIV infected and exposed children needs further investigation.  
 
Diarrhoea and low-grade fever have been reported as important clinical features associated with NoV 
infection. In an attempt to find the duration of diarrhoea associated with NoV infection, we found that 
only 18/41 (44 %) of NoV positive children had diarrhoea for about 3 days at the time of specimen 
collection while 15/41 (36.5 %) had diarrhoea for 4 to 5 days and only 6/41 (14.6 %) have had diarrhoea 
for 6 days or more. The duration of diarrhoea did not differ between NoV positive and NoV negative 
patients (p > 0.05). In the current study, fever was defined as > 38.5 ⁰C and we found that only 22/182 
(12 %) of all patients enrolled had fever with most of these  (8 %) being NoV negative children. There 
was therefore no statistical significance (p > 0.05) between NoV positive and NoV negative individuals 
regarding fever. Height and weight was used to calculate body mass index (BMI) of the children to 
compare their nutritional status. Malnutrition generally results not only in a reduced ability to control 
infections but also in a reduced ability to develop protective immunity toward sub-sequent re-infections 
(Chandra, 1983; von Bubnoff, 2011). This was also reflected in our study, where malnourished 
(underweight) children made up 145/182 (80 %) of our study participants. The prevalence NoV 
infection was with 80 % higher in malnourished as compared to children (14.6 %) with normal BMI. 
We could not determine whether BMI was associated with the rate at which NoV infection cleared as 
this was a cross-sectional study. 
 
Multiple preventive and therapeutic interventions have been designed to decrease mortality and 
disability in children. Among these, early and exclusive breastfeeding is one of the most important 
interventions to reduce neonatal and infant mortality (Walker et al., 2011). Breastfeeding is widely 
promoted (Bhutta et al., 2013) and is the most cost effective intervention for protecting children against 
diarrhoea and all other causes of mortality (Jones et al., 2003). Human breast milk helps protect infants 
by serving as a source of nutrition uncontaminated by environmental pathogens in addition to the direct 
protection due to its multiple anti-microbial, anti-inflammatory and immune-regulatory components 
(Morrow & Rangel, 2004). Breastfeeding demonstrates a dose–response relationship of protection 
against morbidity and mortality in infancy by diarrheal disease. Exclusive breastfeeding, defined as 
feeding only human milk with no other liquids or foods, is known to offer maximum protection against 
diarrhoea in infants younger than 6 months of age, whereas partial breastfeeding offers intermediate 
protection compared with no breastfeeding. The proportion of partially breastfed infants increases with 
age (Arifeen et al., 2001). Improvements in breastfeeding practices can be achieved through various 
educational and promotional strategies. Paediatricians play a critical role by supporting and motivating 
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a successful mother-infant breastfeeding dyad (Section on Breastfeeding, 2012). Breastfeeding 
promotion remains an intervention of enormous public health potential. It is one of the most cost-
effective child health interventions currently available and does not require extensive health system 
infrastructure. These characteristics, along with the large disease burden associated with suboptimal 
breastfeeding, indicate that breastfeeding promotion has the potential to improve child health outcomes 
(Roberts et al., 2013). NoV infection occurs less often in infants of mothers with higher levels of lacto-
N-difucohexaose (a 2-linked fucosyl-oligosaccharide) in their milk (Morrow et al., 2005), as this 
protects against this virus by blocking the binding to the histo-blood group antigen receptors (Morrow 
et al., 2005). We observed no difference between children that were exclusively breastfed 7/13 (54 %) 
and children that were mixed fed 6/13 (46 %). This might be on the account of the small numbers. 
 
As this study was part of a bigger study, where other non-bacterial aetiologies were like RoV were 
investigated, the result of those studies were compared with ours. We discovered a prevalence of 79/182 
(43.4 %) for RoV compared to 41/182 (22.5%) for NoV. This prevalence was consistent with what has 
been found in other settings (Mans et al., 2016). The peak incident of infection for RoV was in children 
≤ 5 months 25/79 (31.6 %) followed by age group 12 - 23 months 23/79 (29.1 %), then age group 6 - 
11 months 18/79 (22.7 %) in children less than 24 months compared to children older with a prevalence 
of 13/79 (16.4 %). This was different from what was observed in children with NoV infection where 
the highest prevalence was in the age group 12 - 23 months 16/41 (39.0 %) followed by the age group 
≤ 5 months and 6 - 11 months each with 11/41 (26.8 %). Other clinical signs and symptoms like fever 
and nutritional status did not differ between NoV and RoV. Both NoV and RoV infected children had 
the highest prevalence in children that were underweight compared to children with healthy weight. 
Only 16/182 (8.8 %) of the children were co-infected with RoV and NoV and from those, 9/16 (56 %) 
of them were in the 12 – 23-month age group. 
Our study has several limitations. This includes the duration of the study, considering that a 3 months 
study period is too short to observe seasonal variability with consequent risk of over- or underestimating 
the annual burden of infection. ELISA detected 9 positives that were not detected by RT-qPCR, these 
positives could be false positive as RT-qPCR did not detect them. This may be due to primers specific 
for GI and GII not including GIV.  
 
4.1 CONCLUSION   
The aim of this study was to detect NoV in children 5 years and under with diarrhoea in KZN. NoVs is 
a public health threat among children, in both developed and developing countries. Our findings showed 
that RT-qPCR is superior to ELISA when detecting NoV in stool specimen.  Our findings also reveiled 
that the circulating genogroup was GII and therefore further investigation on genotyping should be done 
to better understand circulating genotypes. The highest prevalence of NoV was seen in children younger 
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than 24 months compared to older children suggesting protective immunity from previous infection in 
the latter.  
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ABSTRACT 
Objective 
To investigate the non-bacterial aetiologies of diarrhoea in children 5 years and under in KwaZulu-
Natal. 
Methods 
Stool specimens were collected between June 2014 and August 2014 from children < 5 years presenting 
with diarrhoea to a regional hospital. Written informed consent was obtained from their parents or 
guardian. Patient information was collected using a structured questionnaire. Enzyme-linked 
immunosorbent assay (ELISA) and Real-time Polymerase chain reaction (RT-PCR) were used for 
detecting rotavirus and norovirus. Protozoa were detected microscopically using the modified trichrome 
stain and the modified Ziehl-Neelsen stain. The data were analysed using SPSS. 
Results 
One hundred and eighty-two stool specimens were collected. A total of 114 (62.6%) children were 
positive for at least one pathogen. Rotavirus had the highest prevalence of 43.3% followed by Norovirus 
with 22.5%, then Cryptosporidium parvum with 9.9% and Giardia lambliae with 2.7%. Co-infection 
with two or more enteric pathogens was detected in 26 (14.2%) children. Rotavirus-Norovirus (7.1%) 
was the most common co-infection, followed by Rotavirus-C. parvum (3.3%) and Rotavirus- G. 
lambliae (0.5%).  
Conclusion 
This study highlights the burden of non-bacterial aetiologies of diarrhoea among children of 5 years 
and under in KwaZulu-Natal. Single infection of viral aetiology was observed in more than half of the 
study population. An effective Norovirus vaccine is urgently needed while Rotavirus vaccination needs 
to be optimised. The potential synergistic effect of multiple infection on the severity of diarrhoea 
especially among children less than 2 years old need further exploration.  
 
Key words: Diarrhoea; Children; Norovirus; Rotavirus; Cryptosporidium parvum; Giardia lambliae  
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INTRODUCTION 
Acute gastroenteritis is the leading cause of mortality in young children globally and an important cause 
of morbidity and hospitalization in developing countries (Kosek et al., 2003; Parashar et al., 1998). It 
affects people of all age but children 5 years and under tend to be more severely ill, especially children 
below 2 years of age because of their immature immunity and rapid dehydration. The prevalence of 
bacterial gastroenteritis diminished along with improved hygiene, sanitation, food and water handling, 
but non-bacterial gastroenteritis remained with viruses as the most important cause in children (Mäki 
et al., 1978; Mäki et al., 1981; Vesikari et al., 1981). These viruses include rotavirus (RoV), norovirus 
(NoV), Astrovirus, Sapovirus and Adenovirus serotype 40 and 41 (Higgins et al., 2011). Of these RoV 
and NoV are most frequently diagnosed.  Both are highly infectious with an infective dose between 10 
and 100 virions and both are transmitted via the faecal oral route and via respiratory droplets, (Ward et 
al., 1986; Said et al., 2008; Mandell et al., 2010). RoV infection can be diagnosed using ELISA antigen 
test, polymerase chain reaction (PCR) and RT-PCR (Pang et al., 1999). Since antigen detection tests 
are relatively insensitive, the importance of NoV in outbreaks of acute gastroenteritis was only 
appreciated with the introduction of RT-PCR (Chen & Hu, 2016). 
 
Giardia lamblia and Cryptosporidium parvum are protozoan parasites that cause acute gastroenteritis. 
Transmission occurs mainly through contact with contaminated food, water, direct contact with infected 
animals or exposure to water contaminated by animal faeces. C parvum are obligate intracellular 
parasites. They are secreted in the intestinal epithelial cells in a form of an oocyst (Laurent et al., 1997). 
In immune deficient individuals such as those infected with HIV and/or malnourished, C. parvum 
causes chronic or persisting diarrhoea and can also infect the biliary tract (Hunter and Nichols, 2002; 
Pantenburg et al., 2008). 
 
G. lamblia can be found in two distinct forms, as cyst and as trophozoite (Faghiri & Widmer, 2011).  
Outside the host it exists as a cyst which is resistant to many environmental stresses except soil 
deposition and cold water in winter (Robertson and Gjerde, 2004). The trophozoites are responsible for 
disease manifestations. They colonize the small intestine and attach to the intestinal wall with a ventral 
disk (Adam, 2001). Trophozoites encyst in the jejunum after nuclear replication. This encystment is 
triggered by host factors like high bile concentration, basic pH and low cholesterol in that part of the 
gut (Lauwaet et al., 2007). C. parvum are intracellular coccoid protozoa that belong to the family 
Cryptosporididae. They have a wide range of hosts including dogs, cats, cattle, mice, deer and fowl. 
Sporulated oocysts of Cryptosporidium parvum are excreted by the infected host with the faeces and 
through other routes such as respiratory secretions. We report on the aetiology other than bacteria of 
acute gastroenteritis in children of 5 years and under, attending a tertiary health care center in KwaZulu-
Natal. 
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METHODOLOGY 
 
Children of 5 years and below presenting with diarrhoea at King Edward VIII Hospital (KEH) in the 
eThekwini district of KwaZulu-Natal were recruited from Monday to Friday from 8:00 till 14:00 
between 1 June 2014 and 30 August 2014. Diarrhoea was defined as 3 or more loose stool within a 24 
hour period (Howard et al., 2017). Informed consent was obtained from parents or guardians. 
Demographic and clinical data captured on a questionnaire and a stool specimen was collected from 
soiled diapers using a wooden spatula. Based on the calculated BMI children were classified as 
underweight, healthy weight, overweight or obese. The body temperature was measured using an 
infrared ear thermometer (HuBDIC Co., Limited, Korea). Fever was defined as a temperature of  
≥38.5 oC (Howard et al., 2017). Blood specimens for HIV testing were collected by means of, the dry 
blood spot (DBS) collection kit. Infant HIV polymerase chain reaction (PCR) was performed using the 
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 (Roche, South Africa). HIV testing was 
done in the laboratory of KEH using PCR. 
 
Stool specimens were transported in a cooler box to the Medical Microbiology laboratory at the Nelson 
R Mandela School of Medicine, adjacent to KEH. The specimens were aliquoted on arrival and stored 
at -80oC until further use. One aliquot was suspended in 10 % formalin for parasitological 
investigations. The ProSpecT™ Rotavirus antigen detection kit and the IDEIA™ Norovirus kit (Oxoid 
Limited, Basingstoke Hampshire, United Kingdom) were used to diagnose the respective viral 
infections. A 10% stool suspension was prepared using sample diluent provided with the kit. The 
suspension was allowed to stand at room temperature for 10 minutes, following which the top layer was 
used for antigen detection according to the manufacturer’s instructions. 
 
Viral ribonucleic acid (RNA) was extracted from a 10% (w/v) stool suspension made in phosphate 
buffered saline (PBS) (PH 7.2) using the QIAamp Viral RNA Mini kit (Qiagen, Germany) according 
to the manufacturer’s instructions. RT-qPCR was performed using the Applied Biosystems® 7500 
Real-Time PCR Systems (Applied Biosystems™, USA) 
 
Viral RNA from the stool specimens were subjected to quantitative PCR (qPCR) specific for Norovirus. 
This qPCR was performed using the RealStar® Norovirus RT-PCR kit (Altona diagnostics, Hamburg, 
Germany). This is a one-step reverse transcription qPCR (RT-qPCR) kit and tests were performed 
according to the manufacturer’s instructions. 
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 Stage Cycle 
Repeats 
Acquisition Temperature Time 
Reverse 
Transcription 
Hold 1 - 50 10:00 min 
Denaturation Hold 1 - 95 10:00 min 
Amplification Cycling 45 - 95 0:15 min 
 √ 98 0:45 min 
 
 In addition to detecting NoV, the qPCR kit also differentiated between the most prevalent NoV 
genogroups which are genogroup I (GI) and genogroup II (GII).  
 
 
Smears prepared with the formalin preserved aliquot were stained with modified trichrome stain to 
diagnose protozoal infections (Hale et al., 1996) and modified Ziehl-Neelsen stain for the diagnoses of 
C. parvum (Hooja et al., 2011). Smears were viewed using light microscopy (Olympus, Japan) at 400X 
magnification for the detection of protozoal parasites.  
 
Statistical Analysis 
The association between the prevalence of the viral, parasitic and co-infections and the categorical 
variables was assessed using the Fisher’s exact test. A p-value <0.05 was considered to be statistically 
significant. The data was analysed using SPSS (version 22). 
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RESULTS 
A total of 182 children were enrolled in this study. Of these, 91 (50 %) and 23 (12.6 %) were infected 
with viruses and protozoa respectively, giving a total of 114 (62.6 %) positives for at least one pathogen. 
Table 1 shows the age and gender distribution of the children together with their clinical features.  Of 
the positives, 53 (46.5 %) were male and 61 (53.5 %) female. RoV was with an overall prevalence of 
43.4 % highest using EIA. This was followed by NoV with an overall prevalence of 22.5 % from the 
RT-PCR. All NoV detected were of Genogroup II. C. parvum was found in 18 (9.9 %) and G. lambliae 
in 5 (2.7 %) of the patients. With regards to single infection, RoV was most common (30.8 %), followed 
by NoV (12.1 %). In addition, 3.3 % and 2.2 % of single infection were attributed to C. parvum and G. 
lamblia species respectively. None of the other protozoal causes of diarrhoea were found. Co-infection 
with two or more enteric pathogens was detected in 26 (14.3 %) children. These co-infections were 
stratified as virus-virus, virus-protozoan and protozoan-protozoan types. The most common co-
infection was the Norovirus-Rotavirus, detected in 13 (7.1 %) of the study population. This was 
followed by the rotavirus-C. parvum combination (3.3 %). The lowest coinfection rate was recorded for 
Rotavirus-G. lamblia (0.5 %). No co-infection was  observed with orovirus and G. lamblia.  
Most patients (163; 89.6 %) were less than 2 years old.  The prevalence of diarrhoeal pathogens was 
higher in this age group as compared to children above this age [99 (54.4 %) vs. 15 (8.2 %), p = 0.04]. 
Further analysis revealed that the presence of multiple infections was not related to age (p = 0.3). Most 
(87.4 %) of the children did not have fever at the time of specimen collection and of these, 62.9% had 
at least one pathogen. Of the (12 %) children that had fever, 60 % has at least one pathogen. There was 
no relationship between the prevalence of pathogen detected among children who had fever and those 
who did not (p = 0.6). In addition, fever was not related to infection with multiple pathogens (p = 0.2). 
Of the total number of children enrolled in the study, 145 (79.7 %) were underweight and 65.5% of 
these had at least one pathogen. Children underweight are more likely to have infection. However, there 
was no relationship between the species of pathogen detected among underweight and healthy weight 
children (p = 0.2). Nighty two (50.5 %) children had a diarrhoeal duration between 1- 3 days and about 
45.6% of children had diarrhoea which lasted for more than 3 days. We observed that there was a greater 
chance of detecting pathogens within the first 3 days of illness. After the 3 days, the rate of detection 
decreased, however this observation was not significant within our study population (p = 0.5). Just over 
half of the patients were HIV negative (55.5 %) and about 57 % of this group harboured at least one 
pathogen. In contrast, only 11 % of children who were HIV positive had one or more pathogens. Thus, 
the prevalence of diarrhoeal pathogens in these children was not influenced by their HIV status (p = 
0.2). When we merged the HIV exposed children with the HIV positive children, we found no statistical 
significance between the prevalence of diarrhoeal pathogens detected in this group and that in the HIV 
negative children (p = 0.09).  
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Information regarding mode of feeding was collected from children of 6 months or younger. Of the 89 
children who fell into this age group 40 (44.9 %) were exclusively breast fed (Table 1). Within the 
exclusively breastfed study population, 21 (52.5 %) harboured at least one pathogen. In contrast, 34 
(69.4 %) of the mixed fed children had at least one pathogen. This difference was not statistically 
significant (p = 0.13).  
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Table 1: The percentage clinical characteristics for Norovirus, Rotavirus and Protozoa for mono-infection, co-infection and triple infection in 
children 5 years and under 
 
                                 NoV = Norovirus; RoV = Rotavirus; Giardia = Giardia lambliae; Crypto = Cryptosporidium parvum; BMI = Body mass index
NoV only RoV only Giardia Crypro
NoV and 
RoV
NoV and 
Giardia
NoV and 
Crypto 
Rov and 
Giardia
RoV and 
Crypto
NoV, RoV and 
Giardia
NoV, RoV 
and Crypto None Total
22 (12.1%) 56 (30.8%) 4 (2.2%) 6 (3.3%) 13 (7.1%) 0 3 (1.6%) 1 (0.5%) 6 (3.3%) 0 3 (1.6%) 68 (37.4%) 182
Age group (n = 182)
≤ 5 Months 6 (27.3%) 19 (34%) 2 (50%) 1 (16.7%) 3 (23.1%) 0 2 (66.7%) 0 3 (50%) 0 0 26 (38.2%) 62 (34.1%)
6 – 11 Months 7 (31.8%) 14 (25%) 0 2 (33.3%) 1 (7.7%) 0 1 (33.3%) 0 1 (16.7%) 0 2 (66.7%) 18 (26.5%) 46 (25.3%)
12 – 23 Months 7 (31.8%) 13 (23.2%) 2 (50%) 3 (50%) 8 (61.5%) 0 0 0 1 (16.7%) 0 1 (33.3%) 20 (29.4%) 55 (30.2%)
24 – 35 Months 1 (4.5%) 6 (10.7%) 0 0 1 (7.7%) 0 0 1 (100%) 1 (16.7%) 0 0 3 (4.4%) 13 (7.1%)
36 – 60 Months 1 (4.5%) 4 (7.1%) 0 0 0 0 0 0 0 0 0 1 (1.5%) 6 (3.3%)
Sex
Male 10 (45.5%) 25 (44.6% 3 (75%) 2 (33.3%) 7 (53.8%) 0 0 1 (100%) 4 (66.7%) 0 1 (33.3%) 40 (58.8%) 93 (51.1%)
Female 12 (54.5%) 31 (55.4%)  1 (25%) 4 (66.7%) 6 (46.2%) 0 3 (100%) 0 2 (33.3%) 0 2 (66.7%) 28 (41.2%)  89 (48.9%)
Fever
Yes (>38.5 ⁰C) 4 (18.2%) 4 (7.1%) 1 (25%) 1 (16.7%) 1 (7.7%) 0 1 (33.3%) 0 0 0 1 (33.3%) 9 (13.2%) 22 (12.1%)
No (≤ 38.5⁰C) 18 (81.8%) 52 (92.9%) 3 (75%) 5 (83.3%) 12 (92.3%) 0 1 (33.3%) 1 (100%) 6 (100%) 0 2 (66.7%) 59 (87.8%) 159 (87.4%)
Unknown 0 0 0 0 0 0 1 (33.3%) 0 0 0 0 0 1 (0.5%)
BMI (n = 182)
Underweight (< 18.5) 19 (86.4%) 48 (85.7%) 3 (75%) 6 (100%) 8 (61.5%) 0 3 (100%) 1 (100%) 4 (66.7%) 0 3 (100%) 50 (73.5%) 145 (79.7%)
Healthy weight (18.5 - 24.9) 1 (4.5%) 4 (7.1%) 1 (25%) 0 5 (38.5%) 0 0 0 0 0 0 11 (16.2%) 22 (12.1%)
Overweight (25 - 29.9) 0 0 0 0 0 0 0 0 0 0 0 1 (1.5%) 1 (0.5%)
Obese (> 30) 0 1 (1.8%) 0 0 0 0 0 0 1 (16.7%) 0 0 2 (2.9%) 4 (2.2%)
Unknown 2 (9.1%) 3 (5.4%) 0 0 0 0 0 0 1 (16.7%) 0 0 4 (5.9%) 10 (5.5%)
Duration of Diarrhoea (n = 182) 
1 – 3 days 9 (40.9%) 32 (57.1%) 3 (75%) 3 (50%) 6 (46.1%) 0 2 (66.7%) 0 3 (50%) 0 1 (33.3%) 33 (48.5%) 92 (50.5%)
4 – 5 days 10 (45.5%) 12 (21.4%) 1 (25%) 1 (16.7%) 4 (30.8%) 0 0 0 2 (33.3%) 0 1 (33.3%) 18 (26.5%) 49 (26.9%)
 ≥ 6 days 3 (13.6%) 10 (17.9%) 0 1 (16.7%) 3 (23.1%) 0 0 1 (100%) 0 0 0 16 (23.5%) 34 (18.7%)
Unknown 0 2 (3.6%) 0 1 (16.7%) 0 0 1 (33.3%) 0 1 (16.7%) 0 1 (33.3%) 1 (1.5%) 7 (3.8%)
HIV status (n = 182)
Positive 3 (13.6%) 4 (7.1%) 1 (25%) 0 2 (15.4%) 0 0 0 1 (16.7%) 0 1 (33.3%) 12 (17.6%) 24 (13.2%)
Negative 13 (59.1%) 38 (67.9%) 3 (75%) 1 (16.7%) 5 (38.5%) 0 2 (66.7%) 1 (100%) 2 (33.3%) 0 0 36 (52.9%) 101 (55.5%)
Exposed 4 (18.2%) 7 (12.5%) 0 4 (66.7%) 2 (15.4%) 0 1 (33.3%) 0 3 (50%) 0 2 (66.7%) 12 (17.6%) 35 (19.2%)
Unknown 2 (9.1%) 7 (12.5%) 0 1 (16.7%) 4 (30.8%) 0 0 0 0 0 0 8 (11.8%) 22 (12.1%)
Mode of Feeding (n = 89)
Breast feeding 4 (50%) 11 (37.9%) 1 (33.3%) 1 (33.3%) 2 (66.7%) 0 1 (50%) 0 1 (25%) 0 0 19 (55.9%) 40 (44.9%)
Mixed feeding 4 (50%) 18 (62.1%) 2 (66.7%) 2 (66.7%) 1 (33.3%) 0 1 (50%) 1 (100%) 3 (75%) 0 2 (100%) 15 (44.1%) 49 (55.1%)
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DISCUSSION 
Diarrhoeal disease is a major contributor to child morbidity and mortality worldwide, especially in low and 
middle-income countries (Lanata et al., 2013). Variable aetiologies of diarrhoea among children of five 
years and below have been recorded in different countries of the world (Shrivastava et al, 2017; Zhang et 
al., 2016; Saeed et al., 2015). This study showed that 62.6% of the children were positive for at least one 
diarrhoea pathogen. As in other studies from South Africa (NHLS, 2013; Seheri et al., 2010), RoV was the 
most commonly diagnosed aetiology in this study. This is in keeping with a previous report from KZN 
where 55 % of diarrhoea cases were attributed to RoV (NHLS, 2013). Noteworthy is the fact that our study 
and the previously reported finding in KZN were conducted in the winter months of the year when RoV is 
most prevalent. The RoV vaccine was included in the national immunization program of South Africa about 
eight years ago and has been reported to effectively reduce the burden of RoV hospitalization (Madhi et al., 
2010). Consequently, NoV may become the most commonly detected aetiology of diarrhoea among 
children less than 5 years old in the nearest future. This speculation was supported by our findings where 
NoV was the second most prevalent pathogen. In addition, all the NoV detected were of genogroup II (GII). 
This is surprising since previous studies in other part of South Africa has reported multiple genogroups of 
NoVs (Kabuea et al., 2016; Mans et al., 2016; Murray et al., 2013).  
The most common co-infection detected was the norovirus-rotavirus combination which correlates with a 
previous report (Zhang et al., 2016). In contrast, rotavirus-Shigella co-infection was observed as the most 
frequent combination in a recent study in India (Shrivastava et al., 2017). However, our study was only 
focused on the non-bacterial aetiologies of diarrhoea. It will be important to conduct a study which 
considers the broad representation of the enteric pathogen community in children of 5 years and under to 
draw a firm conclusion regarding the prevalence of co-infections of diarrhoeal pathogens. Such a study 
should take seasonal differences into account. Although we did not analyse the influence of co-infection on 
severity of diarrhoea, but it was reported previously that co-infection might lead to a higher severity and 
complications of diarrhoea than infection with single pathogens (Shrivastava et al., 2017).  
Few studies have highlighted the role of intestinal protozoa as an important aetiology of diarrhoeal disease 
in South Africa especially in KwaZulu-Natal (Iyaloo et al., 2015; Jarmey-Swan et al., 2001). In our study, 
intestinal protozoa were less frequently detected as compared to viruses. We observed that 3.3 % and 2.2 
% of diarrhoeal cases were due to C. parvum and G. lamblia respectively. In contrast, a study among 
diarrhoeic children of 0 – 59 months old in rural Mozambique reported Cryptosporidium and G. lamblia as 
the most frequently detected diarrhoea aetiology after rotavirus (Nhampossa et al., 2015). This disparity 
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may be attributed to the difference in socioeconomic conditions in the study areas. Therefore, a higher 
prevalence of diarrhoea pathogens is expected in the rural area of Mozambique in comparison to the urban 
area of KZN.  
Most of the children enrolled in this study were less than 2 years old and diarrhoeal pathogen detection was 
significantly higher in this age group as previous reported in another study (Nhampossa et al., 2015). This 
observation may be due to the poorly developed immune system of these children or due to waning natural 
immunity acquired transplacentally or via breast milk. The lower prevalence of diarrhoeal pathogen in the 
above 2 years age group is not surprising since it was previously reported that protection against some of 
these pathogens such as RoV is developed following subsequent infection in the earlier years (Clark and 
Desselberger, 2015; Desselberger & Huppertz, 2011). A study in Finland reported that 89.3% of diarrhoea 
patients had fever and that higher temperature shows that there is an increase in the severity of an infection 
(Hemming et al., 2014). They found a significantly higher RoV infection among children who had fever 
(Hemming et al., 2014). However, most of the children (87.4 %) in our study did not have fever at the time 
of specimen collection, and more than half of these patient had at least one infection.  
The most widely used indicator for assessing undernutrition in children is weight measurement. 
Underweight is associated with undernutrition which leads to immune depression and increased risk of 
infections. We observed that about 80% of the children enrolled in our study were underweight and more 
than half of them had at least one diarrhoeal pathogen. This observation is consistent with a previous study 
in India where underweight children had a significantly higher prevalence of diarrhoea and infection in 
comparison to healthy weight children (Ramachandran and Gopalan, 2009). The statistically insignificant 
observation in our study regarding the prevalence of infection among underweight and healthy weight 
children shows that being underweight is not the only indictor for acquisition of infection among children 
with diarrhoea in KZN.  
The effect of HIV on the immune system and the subsequent infection acquisition among HIV infected 
individuals has been widely studied. A study in Kenya revealed a higher prevalence of diarrhoea among 
HIV positive than HIV negative children. However, they reported that diarrhoeic HIV positive children 
were less likely to harbour bacterial pathogens than diarrhoeic negative children (Van-Eijk et al., 2010). 
Similarly, in this study we observed that children who are HIV negative with HIV negative parents are 
more likely to have non-bacterial diarrhoeic infection than children who are HIV positive or HIV exposed. 
This could be the result of a higher prevalence of diarrhoea of non-infective origin such as increased 
malabsorption and metabolic enteritis (Van-Eijk et al., 2010). In addition, a study in South Africa associated 
the use of trimethoprim-sulfamethoxazole prophylaxis to an increased risk of diarrhoea in both HIV 
infected and exposed infants (Coutsoudis et al., 2005). The advantage of exclusive breast feeding among 
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infants of HIV infected and uninfected mothers to diarrhoea morbidity and mortality in KZN has been 
previously documented (Rollins et al., 2013). In this study, there was a tendency of higher infection rates 
among children who were mixed fed than the exclusively breastfed children irrespective of their HIV status. 
Although this observation was not significant, but it suggests that exclusive breast feeding potentially 
reduce diarrhoeal pathogen in the study population. A higher sample size may give us a better understanding 
of the effect of exclusive breastfeeding on the prevalence of diarrhoeal pathogen among infants and young 
children. 
This hospital based study highlights the burden of major non-bacterial aetiologies of diarrhoea among 
children of five years and under in KZN. Single infection of viral origin as shown in more than half of our 
study population raises significant questions regarding the role of bacterial and parasitic pathogens in 
diarrhoeal disease. The potential synergistic effect during multiple infection in the overall pathogenesis of 
diarrhoeal diseases can only be understood when the overall burden of enteric pathogens is evaluated. The 
inability of laboratories in low income countries to detect some of these pathogens poses significant 
problems for treatment and infection control. Improved awareness about infection prevention and control, 
improve access to safe water, sanitation and hygiene, and the availability of zinc and vitamin A 
supplementation are measures to prevent and reduce the burden of diarrhoeal diseases in low and middle-
income countries including South Africa.  
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
Funding 
The authors wish to thank the College of Health Sciences in the University of KwaZulu-Natal and the South 
African National Research Foundation for their financial support for this study. These funding sources had 
no role in the study design, collection, analysis and interpretation of data; in the writing of the manuscript 
and in the decision to submit this manuscript for publication. 
Ethics approval 
This study was approved by the Biomedical Research Ethics Committee of the University of KwaZulu-
Natal in accordance with its ethical standards and with the 1964 Helsinki declaration. 
Informed consent 
Informed consent was obtained from the parents or guardian of all individual participants included in this 
study. 
Author contributions 
A Willem Sturm, Prashini Moodley and Osaretin E. Asowata designed the study. Osaretin E. Asowata, 
Nelisiwe V Nxele and Nakita Reddy participated in the sample collection and data management. Nelisiwe 
V Nxele, Osaretin E. Asowata, Nakita Reddy and Olubisi T. Ashiru participated in sample analysis. 
Nelisiwe V Nxele and Osaretin E. Asowata prepared the first draft of the manuscript. A. Willem Sturm and 
Prashini Moodley revised the manuscript. All authors participated in the preparation of manuscript and 
approved the final version for publication. 
Acknowledgement 
The authors wish to thank the study participants, Dr. Moherndran Archary, Dr. Shashikant Ramji and all of 
the staff of the paediatric department of King Edward VIII Hospital, University of KwaZulu-Natal. In 
addition, the authors wish to acknowledge the assistance of Ms. Cathy Connolly of the Department of Public 
Health Medicine in the University of KwaZulu-Natal, South Africa. 
Conflict of interest Statement: The authors declare that they have no conflict of interest. 
 
 
 
 
42 
 
REFERENCES 
1. Adam RD. Biology of Giardia lamblia. Clinical Microbiology Reviews 2001; 14(3): 447–75. 
http://www.ncbi.nlm.nih.gov/pubmed/11432808 [Accessed March 1, 2017]. 
2. Clark E and Desselberger U. Correlates of protection against human rotavirus disease and the factors 
influencing protection in low-income settings. Mucosal Immunology 2015; 8(1). 
3. Coutsoudis A, Pillay K, Spooner E, Coovadia HM, Pembrey L and Newell ML. Routinely available 
cotrimoxazole prophylaxis and occurrence of respiratory and diarrhoeal morbidity in infants born to 
HIV-infected mothers in South Africa. South African Medical Journal 2005; 95: 339–45. 
4. Desselberger U and Huppertz H. Immune responses to rotavirus infection and vaccination, and 
associated correlates of protection. Journal of Infectious Diseases 2011; 203: 188–95. 
5. Desselberger U. Rotaviruses. Virus Research 2014; 190: 75–96.  
http://www.ncbi.nlm.nih.gov/pubmed/25016036 [Accessed August 3, 2017]. 
6. Dobell C. The Discovery of the Intestinal Protozoa of Man. Proceedings of the Royal Society of 
Medicine 1920; 13(Sect Hist Med): 1–15. http://www.ncbi.nlm.nih.gov/pubmed/19981292 
[Accessed March 1, 2017]. 
7. Ettayebi K, Crawford SE, Murakami K, Broughman JE, Karandikar U, Tenge VR, et al. Replication of 
human noroviruses in stem cell – derived human enteroids. Science 2016; 353(6306): 1387–93.  
8. Faghiri Z and Widmer G. A comparison of the Giardia lamblia trophozoite and cyst transcriptome 
using microarrays. BMC Microbiology 2011; 11(1): 91. 
http://bmcmicrobiol.biomedcentral.com/articles/10.1186/1471-2180-11-91. [Accessed August 4, 
2017]. 
9. Hale DC, Carroll K, Kucera JR and Aldeen WE. Use of a Single Slide Trichrome-Stained Concentrate 
for the Detection of Intestinal Parasites. American Journal of Clinical Pathology 1996; l06(2). 
http://webcache.googleusercontent.com/search?q=cache:zeF9U85cTuQJ:www.hemode.com/articles
/Article%25203.pdf+&cd=5&hl=en&ct=clnk&client=firefox-b. [Accessed August 4, 2017]. 
10. Higgins RR, Beniprashad M, Cardona M, Masney S, Low DE and Gubbay JB. Evaluation and 
verification of the Seeplex Diarrhea-V ACE assay for simultaneous detection of adenovirus, 
rotavirus, and norovirus genogroups I and II in clinical stool specimens. Journal of Clinical 
Microbiology 2011; 49(9): 3154–62. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3165607&tool=pmcentrez&rendertype=
43 
 
abstract [Accessed June 2, 2016]. 
11. Hemming M, Huhti L, Räsänen S, Salminen M and Vesikari T. Rotavirus antigenemia in children is 
associated with more severe clinical manifestations of acute gastroenteritis. Pediatric Infectious 
Disease Journal 2014; 33: 366–71 
12. Hooja S, Pal N, Malhotra B, Goyal S, Kumoar V and Vyas L. Comparison of Ziehl Neelsen &amp; 
Auramine O staining methods on direct and concentrated smears in clinical specimens. The Indian 
Journal of Tuberculosis 2011; 58(2): 72–6. http://www.ncbi.nlm.nih.gov/pubmed/21644393 
[Accessed August 4, 2017]. 
13. Howard LM, Mwape I, Siwingwa M, Simuyandi M, Guffey MB, Stringer JSA, et al. Norovirus 
infections in young children in Lusaka Province, Zambia: clinical characteristics and molecular 
epidemiology. BMC infectious diseases 2017; 17(1): 92. 
http://www.ncbi.nlm.nih.gov/pubmed/28114885 [Accessed August 4, 2017]. 
14. Iyaloo S, Keddy K, Page N, Poonsamy B, Cohen C and Frean J. Non-viral causes of diarrhoea in 
children less than 5 years from sentinel sites in South Africa, 2009–2013. Communicable Diseases 
Surveillance Bulletin 2015; 13: 2.  
15. Jarmey-Swan C, Bailey IW and Howgrave-Graham AR. Ubiquity of the water-borne pathogens, 
Cryptosporidium and Giardia, in KwaZulu-Natal populations. Water SA 2001; 27: 1. 
16. Kabuea JP, Meader E, Hunter PR and Potgieter N. Norovirus prevalence and estimated viral load in 
symptomatic and asymptomatic children from rural communities of Vhembe district, South Africa. 
Journal of Clinical Virology 2016; 84: 12–8 
17. Hunter PR. and Nichols G. Epidemiology and clinical features of Cryptosporidium infection in 
immunocompromised patients. Clinical Microbiology Reviews 2002; 15(1): 145–54. 
http://www.ncbi.nlm.nih.gov/pubmed/11781272 [Accessed September 4, 2017]. 
18. Kosek M, Bern C and Guerrant RL. The global burden of diarrhoeal disease, as estimated from 
studies published between 1992 and 2000. Bulletin of the World Health Organization 2003; 81(3): 
197–204. http://www.ncbi.nlm.nih.gov/pubmed/12764516 [Accessed February 27, 2017]. 
19. Laurent F, Eckmann L, Savidge TC, Morgan G, Theodos C, Naciri M, et al. Cryptosporidium parvum 
infection of human intestinal epithelial cells induces the polarized secretion of C-X-C chemokines. 
Infection and Immunity 1997; 65(12): 5067–73. http://www.ncbi.nlm.nih.gov/pubmed/9393797 
[Accessed September 4, 2017]. 
44 
 
20. Lauwaet T, Davids BJ, Reiner DS and Gillin FD. Encystation of Giardia lamblia: a model for other 
parasites. Current Opinion in Microbiology 2007; 10(6): 554–9. 
http://www.ncbi.nlm.nih.gov/pubmed/17981075 [Accessed March 1, 2017]. 
21. Lopman B. Global Burden of Norovirus and Prospects for Vaccine Development 2015; 46. 
http://www.cdc.gov/norovirus/downloads/global-burden-report.pdf. [Accessed March 26, 2017]. 
22. Madhi SA, Cunliffe NA, Steele AD, Witte D, Kirsten M, Louw C et al. Effect of human rotavirus 
vaccine on severe diarrhoea in Africa infants. New England Journal of Medicine 2010; 362: 289–98. 
23. Mäki M. A prospective clinical study of Rotavirus Diarrhoea in young children. Acta Paediatrica 
1981; 70(1):107–13. http://doi.wiley.com/10.1111/j.1651-2227.1981.tb07181.x [Accessed February 
27, 2017]. 
24. Mäki M, Grönroos P and Vesikari T . Role of bacteria and viruses in the etiology of acute 
gastroenteritis in children. Duodecim 1978; 94(12): 790–801. 
http://www.ncbi.nlm.nih.gov/pubmed/211023 [Accessed February 27, 2017]. 
25. Mandell GL, Bennett JE, John E and Dolin R. Mandell, Douglas, and Bennett’s principles and 
practice of infectious diseases 2010, Churchill Livingstone/Elsevier. 
26. Mans J, Murray TY, Nadan S, Netshikweta R, Page NA and Taylor MB. Norovirus diversity in 
children with gastroenteritis in South Africa from 2009 to 2013: GII.4 variants and recombinant 
strains predominate. Epidemiology and Infection 2016; 144(5): 907–16. DOI: 
https://doi.org/10.1017/S0950268815002150. 
27. Marks PJ, Vipond IB, Carlisle D, Deakin D, Fey RE and Caul EO. Evidence for airborne transmission 
of Norwalk-like virus (NLV) in a hotel restaurant. Epidemiology and infection 2000; 124(3): 481–7. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2810934&tool=pmcentrez&rendertype=
abstract [Accessed May 30, 2016]. 
28. Murray TY, Mans J, and Taylor MB. Human calicivirus diversity in wastewater in South Africa. 
Journal of Applied Microbiology 2013; 114: 1843–53. 
29. Nhampossa T, Mandomando I, Acacio S, Quintó L, Vubil D, Ruiz J, et al. Diarrheal Disease in Rural 
Mozambique: Burden, Risk Factors and Etiology of Diarrheal Disease among Children Aged 0-59 
Months Seeking Care at Health Facilities. PLoS One 2015; 10(5): e0119824. Doi: 
10.1371/journal.pone.0119824.   
30. NHLS. Rotavirus Season 2013, Press release. http://www.nhls.ac.za/?page=alerts&id=5&rid=251 
45 
 
(Accessed on 20 March, 2016). 
31. Pang XL, Joensuu J, Hoshino Y, Kapikian AZ and Vesikari T. Rotaviruses detected by reverse 
transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human 
reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysis. Journal of 
clinical virology 1999; 13(1–2): 9–16. http://www.ncbi.nlm.nih.gov/pubmed/10405887 [Accessed 
August 4, 2017]. 
32. Pantenburg B, Dann SM, Wang H, Robinson P, Castellanos-Gonzalez A, Lewis DE, et al. Intestinal 
immune response to human Cryptosporidium sp. infection. Infection and immunity 2008; 76(1): 23–
9. http://www.ncbi.nlm.nih.gov/pubmed/17967863 [Accessed September 4, 2017]. 
33. Parashar UD, Dow L, Fankhauser R L, Humphrey CD,  Miller J, Ando T, et al. An outbreak of viral 
gastroenteritis associated with consumption of sandwiches: implications for the control of 
transmission by food handlers. Epidemiology and infection 1998; 121(3): 615–21. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2809569&tool=pmcentrez&rendertype=
abstract [Accessed May 30, 2016]. 
34. Ramachandran P and Gopalan HS. Undernutrition & risk of infections in preschool children. Indian 
Journal of Medical Research 2009; 130: 579-83. 
35. Robertson LJ and Gjerde BK. Effects of the Norwegian Winter Environment on Giardia Cysts and 
Cryptosporidium Oocysts. Microbial Ecology 2004; 47(4): 359–65. 
http://www.ncbi.nlm.nih.gov/pubmed/14749905 [Accessed March 1, 2017]. 
36. Rollins NC, Ndirangu J, Bland RM, Coutsoudis A, Coovadia HM and Newell M. Exclusive 
breastfeeding, diarrhoeal morbidity and all-cause mortality in infants of HIV-infected and HIV 
uninfected mothers: An Intervention Cohort Study in KwaZulu Natal, South Africa. PLoS ONE 
2013; 8(12): e81307. doi:10.1371/journal.pone.0081307. 
37. Saeed A, Abd H and Sandstrom G. Microbial aetiology of acute diarrhoea in children under five years 
of age in Khartoum, Sudan Journal of Medical Microbiology 2015; 64: 432–7. 
doi:10.1099/jmm.0.000043. 
38. Said M.A, Perl TM and Sears CL. Healthcare Epidemiology: Gastrointestinal Flu: Norovirus in 
Health Care and Long‐Term Care Facilities. Clinical Infectious Diseases 2008; 47(9): 1202–8. 
http://www.ncbi.nlm.nih.gov/pubmed/18808354 [Accessed September 7, 2017]. 
39. Seheri LM, Dewar JB, van der Merwe L, Geyer A, Tumbo J, Zweygarth M, et al. Prospective 
46 
 
hospital-based surveillance to estimate rotavirus disease burden in the Gauteng and North West 
Province of South Africa during 2003–2005. Journal of Infectious Diseases 2010; S131–8. 
40. Shrivastava AK, Kumar S, Mohakud NK, Suar M and Sahu PS. Multiple etiologies of infectious 
diarrhea and concurrent infections in a pediatric outpatient‐based screening study in Odisha, India. 
Gut Pathogens 2017; 9: 16. doi:10.1186/s13099-017-0166-0.  
41. Van-Eijk AM, Brooks JT, Adcock PM, Garrett V, Eberhard M, Rosen DH, et al. Diarrhea in children 
less than two years of age with known HIV status in Kisumu, Kenya. International Journal of 
Infectious Diseases 2010; 14: e220–e225. 
42. Vesikari T, Mäki M, Sarkkinen H Arstila P and Halonen P. Rotavirus . adenovirus, and non-viral 
enteropathogens in diarrhoea. Archives of Disease in Childhood 1981; 56: 264–70. 
43. Vinjé J. Advances in laboratory methods for detection and typing of norovirus. Journal of clinical 
microbiology 2015; 53(2): 373–81. http://www.ncbi.nlm.nih.gov/pubmed/24989606. [Accessed 
May 26, 2016]. 
44. Ward RL, Bernstein DI, Young EC, Sherwood JR, Knowlton DR and Schiff GM . Human rotavirus 
studies in volunteers: determination of infectious dose and serological response to infection. The 
Journal of infectious diseases 1986; 154(5): 871–80. http://www.ncbi.nlm.nih.gov/pubmed/3021869 
[Accessed March 1, 2017]. 
45. White PA. Evolution of norovirus. Clinical Microbiology and Infection 2014; 20(8): 741–5. 
https://doi.org/10.1111/1469-0691.12746.  
46. Zhang S, Zhou Y, Xu W, Tian L, Chen J, Chen S, et al. Infectious Diseases of Poverty 2016; 5: 64. 
doi:10.1186/s40249-016-0157-2. 
 
 
 
 
 
 
 
47 
 
REFERENCES 
 
Abugalia M, Cuevas L, Kirby A, Dove W, Nakagomi O, Nakagomi T, et al.. . Clinical features and 
molecular epidemiology of rotavirus and norovirus infections in Libyan children. Journal of 
Medical Virology2011, 83(10), 1849–56. https://doi.org/10.1002/jmv.22141 
Adam RD. Biology of Giardia lamblia. Clinical Microbiology Reviews 2001, 14(3), 447–475. 
https://doi.org/10.1128/CMR.14.3.447-475.2001 
Addiss DG, Stewart JM, Finton R.J, Wahlquist SP, Williams RM, Dickerson JW, et al. Giardia lamblia 
and Cryptosporidium infections in child day-... : The Pediatric Infectious Disease Journal. Pediatric 
Infectious Disease Journal 1991. Retrieved from 
http://journals.lww.com/pidj/Abstract/1991/12000/Giardia_lamblia_and_Cryptosporidium_infection
s_in.5.aspx 
Adler JL.& Zickl R. Winter vomiting disease. The Journal of Infectious Diseases 1969, 119(6), 668–73. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/5795109 
Agus SG, Dolin R, Wyatt RG, Tousimis AJ & Northrup RS. Acute infectious nonbacterial gastroenteritis: 
intestinal histopathology. Histologic and enzymatic alterations during illness produced by the 
Norwalk agent in man. Annals of Internal Medicine 1973, 79(1), 18–25. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/4721173 
Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD. Global prevalence of 
norovirus in cases of gastroenteritis: a systematic review and meta-analysis. The Lancet. Infectious 
Diseases 2014, 14(8), 725–30. https://doi.org/10.1016/S1473-3099(14)70767-4 
Amar CFL, East CL, Gray J, Iturriza-Gomara M, Maclure EA & McLauchlin J. Detection by PCR of 
eight groups of enteric pathogens in 4,627 faecal samples: re-examination of the English case-
control Infectious Intestinal Disease Study (1993-1996). European Journal of Clinical Microbiology 
& Infectious Diseases : Official Publication of the European Society of Clinical Microbiology 2007, 
26(5), 311–23. https://doi.org/10.1007/s10096-007-0290-8 
Angel J, Franco MA & Greenberg HB. Rotavirus immune responses and correlates of protection. Current 
Opinion in Virology 2012, 2(4), 419–25. https://doi.org/10.1016/j.coviro.2012.05.003 
Aoki Y, Suto A, Mizuta K, Ahiko T, Osaka K & Matsuzaki Y. Duration of norovirus excretion and the 
longitudinal course of viral load in norovirus-infected elderly patients. The Journal of Hospital 
Infection 2010, 75(1), 42–6. https://doi.org/10.1016/j.jhin.2009.12.016 
Armah GE, Gallimore CI, Binka FN, Asmah RH, Green J, Ugoji U. Characterisation of norovirus strains 
in rural Ghanaian children with acute diarrhoea. Journal of Medical Virology 2006, 78(11), 1480–5. 
https://doi.org/10.1002/jmv.20722 
Atmar J & Mullen E. Norovirus in immunocompromised patients. Oncology Nursing Forum 2013, 40(5), 
434–6. https://doi.org/10.1188/13.ONF.434-436 
Atmar RL, Opekun AR., Gilger MA, Estes MK, Crawford SE, Neill FH, et al.. Norwalk virus shedding 
after experimental human infection. Emerging Infectious Diseases 2008, 14(10), 1553–7. 
https://doi.org/10.3201/eid1410.080117 
Backer HD. Giardiasis. The Physician and Sportsmedicine 2000, 28(7), 46–57. 
48 
 
https://doi.org/10.3810/psm.2000.07.1079 
Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA & Estes MK. Recombinant Norwalk virus-
like particles given orally to volunteers: phase I study. Gastroenterology 1999, 117(1), 40–8. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10381908 
Barker J, Vipond IB & Bloomfield SF. Effects of cleaning and disinfection in reducing the spread of 
Norovirus contamination via environmental surfaces. The Journal of Hospital Infection 2004, 58(1), 
42–9. https://doi.org/10.1016/j.jhin.2004.04.021 
Belliot G, Lopman BA, & Pothier P. The burden of norovirus gastroenteritis : an important foodborne and 
healthcare-related infection. Clinical Microbiology and Infection 2014, 20 (8), 724-730. Elsevier 
Benmessaoud R, Jroundi I, Nezha M, Moraleda C, Tligui H, Seffar M, et al. Aetiology, epidemiology and 
clinical characteristics of acute moderate-to-severe diarrhoea in children under 5 years of age 
hospitalized in a referral paediatric hospital in Rabat, Morocco. Journal of Medical Microbiology 
2015, 64(Pt 1), 84–92. https://doi.org/10.1099/jmm.0.079830-0 
Bern C, Martines J, de Zoysa I & Glass RI . The magnitude of the global problem of diarrhoeal disease: a 
ten-year update. Bulletin of the World Health Organization 1992, 70(6), 705–14. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/1486666 
Bok K, Abente EJ, Realpe-Quintero M, Mitra T, Sosnovtsev SV, Kapikian AZ, et al. Evolutionary 
dynamics of GII.4 noroviruses over a 34-year period. Journal of Virology 2009, 83(22), 11890–901. 
https://doi.org/10.1128/JVI.00864-09 
Boon D, Mahar JE, Abente EJ, Kirkwood CD, Purcell RH, Kapikian AZ et al.. Comparative evolution of 
GII.3 and GII.4 norovirus over a 31-year period. Journal of Virology 2011, 85(17), 8656–66. 
https://doi.org/10.1128/JVI.00472-11 
Bruggink LD, Catton MG & Marshall JA. Evaluation of the Bioline Standard Diagnostics SD 
immunochromatographic norovirus detection kit using fecal specimens from Australian 
gastroenteritis incidents. Diagnostic Microbiology and Infectious Disease 2013, 76(2), 147–52. 
https://doi.org/10.1016/j.diagmicrobio.2013.02.018 
Bruins MJ, Wolfhagen MJHM, Schirm J & Ruijs GJHM. Evaluation of a rapid immunochromatographic 
test for the detection of norovirus in stool samples. European Journal of Clinical Microbiology & 
Infectious Diseases : Official Publication of the European Society of Clinical Microbiology 2010, 
29(6), 741–3. https://doi.org/10.1007/s10096-010-0911-5 
Bucardo F, Nordgren J, Carlsson B, Paniagua M, Lindgren PE, Espinoza F,et al.. Pediatric norovirus 
diarrhea in Nicaragua. Journal of Clinical Microbiology 2008, 46(8), 2573–80. 
https://doi.org/10.1128/JCM.00505-08 
Bull RA, Eden JS, Rawlinson WD & White PA. Rapid evolution of pandemic noroviruses of the GII.4 
lineage. PLoS Pathogens 2010, 6(3), e1000831. https://doi.org/10.1371/journal.ppat.1000831 
Bull RA, Tu ETV, McIver CJ, Rawlinson WD & White PA. Emergence of a new norovirus genotype II.4 
variant associated with global outbreaks of gastroenteritis. Journal of Clinical Microbiology 2006, 
44(2), 327–33. https://doi.org/10.1128/JCM.44.2.327-333.2006 
Bull RA & White PA. Mechanisms of GII.4 norovirus evolution. Trends in Microbiology 2011, 19(5), 
233–40. https://doi.org/10.1016/j.tim.2011.01.002 
49 
 
Cannon JL, Lindesmith LC, Donaldson EF, Saxe L, Baric RS,& Vinjé J. Herd immunity to GII.4 
noroviruses is supported by outbreak patient sera. Journal of Virology 2009, 83(11), 5363–74. 
https://doi.org/10.1128/JVI.02518-08 
Casemore DP. Epidemiological aspects of human cryptosporidiosis. Epidemiology and Infection 1990, 
104(1), 1–28. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2407541 
CDC (Centers for Disease Control and Prevention). Outbreak of acute gastroenteritis associated with 
Norwalk-like viruses among British military personnel--Afghanistan, May 2002. MMWR. Morbidity 
and Mortality Weekly Report 2002, 51(22), 477–9. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/12064451 
CDC, (Centers for Disease Control and Prevention). . Outbreak of Acute Gastroenteritis Associated with 
Norwalk-Like Viruses Among British Military Personnel --- Afghanistan, May 2002. Retrieved May 
30, 2016, from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5122a1.htm 
Chadwick D & Goode J. Gastroenteritis viruses 2001. Wiley. 
Chan WK, Penaranda ME, Crawford SE & Estes MK. Two glycoproteins are produced from the rotavirus 
neutralization gene. Virology 1986, 151(2), 243–52. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/3010552 
Chang KO, Sosnovtsev SV, Belliot G, Kim Y, Saif LJ & Green KY. Bile acids are essential for porcine 
enteric calicivirus replication in association with down-regulation of signal transducer and activator 
of transcription 1. Proceedings of the National Academy of Sciences of the United States of America 
2004, 101(23), 8733–8. https://doi.org/10.1073/pnas.0401126101 
Chang KO, Sosnovtsev SV, Belliot G, King AD & Green KY Stable expression of a Norwalk virus RNA 
replicon in a human hepatoma cell line. Virology 2006, 353(2), 463–73. 
https://doi.org/10.1016/j.virol.2006.06.006 
Chen R, Neill JD, Noel JS, Hutson AM, Glass RI, Estes MK, et al.. Inter- and intragenus structural 
variations in caliciviruses and their functional implications. Journal of Virology 2004, 78(12), 6469–
79. https://doi.org/10.1128/JVI.78.12.6469-6479.2004 
Chen XM, Keithly JS, Paya CV & LaRusso NF. Cryptosporidiosis. New England Journal of Medicine 
2002, 346(22), 1723–1731. https://doi.org/10.1056/NEJMra013170 
Clark DP. New insights into human cryptosporidiosis. Clinical Microbiology Reviews 1999, 12(4), 554–
63. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10515902 
Clarke IN & Lambden PR. The molecular biology of caliciviruses. Journal of General Virology 1997, 
78(2), 291–301. https://doi.org/10.1099/0022-1317-78-2-291 
Clarke IN & Lambden PR. Organization and expression of calicivirus genes. The Journal of Infectious 
Diseases 2000, 181 Suppl, S309-16. https://doi.org/10.1086/315575 
Clarke IN, Estes MK, Green, KY, Hansman GS, Knowles NJ, Koopmans MK, et al . Caliciviridae, Virus 
Taxonomy: The Classification and Nomenclature of Viruses. Molecular Virology 2012. The ninth 
report of the International Committee on Taxonomy of Viruses. Academic Press, London, U.K. p. 
977-986. 
Colas de la Noue A, Estienney M, Aho S, Perrier-Cornet JM, de Rougemont A, Pothier P, et al. Absolute 
Humidity Influences the Seasonal Persistence and Infectivity of Human Norovirus. Applied and 
50 
 
Environmental Microbiology 2014, 80(23), 7196–205. https://doi.org/10.1128/AEM.01871-14 
Coupe S, Sarfati C, Hamane S & Derouin F. Detection of Cryptosporidium and Identification to the 
Species Level by Nested PCR and Restriction Fragment Length Polymorphism. Journal of Clinical 
Microbiology 2005, 43(3), 1017–1023. https://doi.org/10.1128/JCM.43.3.1017-1023.2005 
Cunliffe NA, Ngwira BM, Dove W, Nakagomi O, Nakagomi T, Perez A, et al. Serotype G12 Rotaviruses, 
Lilongwe, Malawi. CC Emerging Infectious Diseases 2009, 15(1), 87–90. 
https://doi.org/10.3201/eid1501.080427 
Current WL & Garcia LS. Cryptosporidiosis. Clinics in Laboratory Medicine 1991, 11(4), 873–97. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1802526 
Danziger-Isakov L, & Kumar D. Vaccination in solid organ transplantation. American Journal of 
Transplantation : Official Journal of the American Society of Transplantation and the American 
Society of Transplant Surgeons 2013, 13 Suppl 4, 311–7. https://doi.org/10.1111/ajt.12122 
de Bruin E, Duizer E, Vennema H,& Koopmans MPG. Diagnosis of Norovirus outbreaks by commercial 
ELISA or RT-PCR. Journal of Virological Methods 2006, 137(2), 259–264. 
https://doi.org/10.1016/j.jviromet.2006.06.024 
De Leon R, Matsui SM, Baric RS, Herrmann JE, Blacklow NR, Greenberg HB, et al. Detection of 
Norwalk virus in stool specimens by reverse transcriptase-polymerase chain reaction and 
nonradioactive oligoprobes. Journal of Clinical Microbiology 1992, 30(12), 3151–7. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=270605&tool=pmcentrez&rendertype=a
bstract 
Debbink K, Lindesmith LC & Baric RS. The state of norovirus vaccines. Clinical Infectious Diseases : An 
Official Publication of the Infectious Diseases Society of America 2014, 58(12), 1746–52. 
https://doi.org/10.1093/cid/ciu120 
Debbink K, Lindesmith LC, Donaldson EF & Baric RS. Norovirus immunity and the great escape. PLoS 
Pathogens 2012, 8(10), e1002921. https://doi.org/10.1371/journal.ppat.1002921 
Derrington P, Schreiber F, Day S, Curtis C & Lyon M. Norovirus Ridaquick: a new test for rapid 
diagnosis of norovirus. Pathology 2009, 41(7), 687–8. https://doi.org/10.3109/00313020903305886 
Desai R, Hembree CD, Handel A, Matthews JE, Dickey BW, McDonald, S, et al. Severe outcomes are 
associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clinical 
Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2012, 
55(2), 189–93. https://doi.org/10.1093/cid/cis372 
Desselberger U & Goodfellow I. Noroviruses: a global cause of acute gastroenteritis. The Lancet. 
Infectious Diseases 2014, 14(8), 664–5. https://doi.org/10.1016/S1473-3099(14)70776-5 
Desselberger U, Wolleswinkel-van den Bosch J, Mrukowicz J, Rodrigo C, Giaquinto C & Vesikari T. 
Rotavirus types in Europe and their significance for vaccination. The Pediatric Infectious Disease 
Journal 2006, 25(1 Suppl), S30-41. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16397427 
Dew K, Keefe V & Small K. “Choosing” to work when sick: workplace presenteeism. Social Science & 
Medicine (1982) 2005, 60(10), 2273–82. https://doi.org/10.1016/j.socscimed.2004.10.022 
Dolin R, Levy AG, Wyatt RG, Thornhill TS & Gardner JD. Viral gastroenteritis induced by the Hawaii 
agent. Jejunal histopathology and serologic response. The American Journal of Medicine 1975, 
51 
 
59(6), 761–8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/811119 
Donaldson EF, Lindesmith LC, LoBue AD  & Baric RS. Viral shape-shifting: norovirus evasion of the 
human immune system. Nature Reviews Microbiology 2010, 8(3), 231–241. 
https://doi.org/10.1038/nrmicro2296 
Doshi M, Woodwell S, Kelleher K, Mangan K & Axelrod P. An outbreak of norovirus infection in a bone 
marrow transplant unit. American Journal of Infection Control 2013, 41(9), 820–3. 
https://doi.org/10.1016/j.ajic.2012.10.025 
Doultree JC, Druce JD, Birch CJ, Bowden DS & Marshall JA. Inactivation of feline calicivirus, a 
Norwalk virus surrogate. The Journal of Hospital Infection  1999, 41(1), 51–7. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9949965 
Dove W, Cunliffe NA, Gondwe JS, Broadhead RL, Molyneux ME, Nakagomi O, et al. Detection and 
characterization of human caliciviruses in hospitalized children with acute gastroenteritis in 
Blantyre, Malawi. Journal of Medical Virology 2005, 77(4), 522–7. 
https://doi.org/10.1002/jmv.20488 
Duizer E, Bijkerk P, Rockx B, De Groot A, Twisk F & Koopmans M. Inactivation of caliciviruses. 
Applied and Environmental Microbiology, 70(8), 4538–43. https://doi.org/10.1128/AEM.70.8.4538-
4543.2004 
Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MPG & Estes MK. Laboratory efforts to cultivate 
noroviruses. The Journal of General Virology 2004, 85(Pt 1), 79–87. 
https://doi.org/10.1099/vir.0.19478-0 
DuPont HL, Chappell CL, Sterling CR, Okhuysen PC, Rose JB & Jakubowski W. The Infectivity of 
Cryptosporidium parvum in Healthy Volunteers. New England Journal of Medicine 1995, 332(13), 
855–859. https://doi.org/10.1056/NEJM199503303321304 
Eden J.-S., Bull, R. A., Tu, E., McIver, C. J., Lyon, M. J., Marshall, J. A., … White, P. A. (2010). 
Norovirus GII.4 variant 2006b caused epidemics of acute gastroenteritis in Australia during 2007 
and 2008. Journal of Clinical Virology : The Official Publication of the Pan American Society for 
Clinical Virology, 49(4), 265–71. https://doi.org/10.1016/j.jcv.2010.09.001 
Eden, JS, Hewitt J, Lim KL, Boni MF, Merif J, Greening, G, et al . The emergence and evolution of the 
novel epidemic norovirus GII.4 variant Sydney 2012. Virology 2014, 450–451, 106–13. 
https://doi.org/10.1016/j.virol.2013.12.005 
Eden JS, Tanaka MM, Boni MF, Rawlinson WD & White PA. Recombination within the pandemic 
norovirus GII.4 lineage. Journal of Virology 2013, 87(11), 6270–82. 
https://doi.org/10.1128/JVI.03464-12 
El Qazoui M, Oumzil H, Baassi L, El Omari N, Sadki K, Amzazi S, et al. Rotavirus and norovirus 
infections among acute gastroenteritis children in Morocco. BMC Infectioud Diseases 2014, 
14(300). https://doi.org/10.1186/1471-2334-14-300 
Erlandsen SL & Meyer EA. Giardia and Giardiasis: Biology, Pathogenesis, and Epidemiology. The 
Quarterly Review of Biology 1985, 60(1), 131–132. https://doi.org/10.1086/414304 
Estes MK, Ball JM, Guerrero RA, Opekun AR, Gilger MA, Pacheco SS, et al. Norwalk Virus Vaccines: 
Challenges and Progress. The Journal of Infectious Diseases, 181(s2), S367–S373. 
52 
 
https://doi.org/10.1086/315579 
Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, et al. Replication of 
human noroviruses in stem cell – derived human enteroids. Science 2016;353(6306): 1387-93.. 
Fang H, Tan M, Xia M, Wang L & Jiang X . Norovirus P particle efficiently elicits innate, humoral and 
cellular immunity. PloS One 2013, 8(4), e63269. https://doi.org/10.1371/journal.pone.0063269 
Fankhauser RL, Noel JS, Monroe SS, Ando T & Glass R I. Molecular Epidemiology of “Norwalk‐like 
Viruses” in Outbreaks of Gastroenteritis in the United States. The Journal of Infectious Diseases 
1998, 178(6), 1571–1578. https://doi.org/10.1086/314525 
Farthing MJG. Immune response-mediated pathology in human intestinal parasitic infection. Par  asite 
Immunology 2003, 25(5), 247–257. https://doi.org/10.1046/j.1365-3024.2003.00633.x 
Fayer R. Effect of high temperature on infectivity of Cryptosporidium parvum oocysts in water. Applied 
and Environmental Microbiology 1994, 60(8), 2732–5. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8085816 
Fayer R, Speer CA & Dubey JP. General biology of Cryptosporidium. Cryptosporidiosis of Man and 
Animals 1990., 1–29. Retrieved from https://www.cabdirect.org/cabdirect/abstract/19910875514 
Fields, B. (2007). Fields virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 
Fischer TK, Viboud C, Parashar U, Malek M, Steiner C, Glass R & Simonsen L. Hospitalizations and 
Deaths from Diarrhea and Rotavirus among Children &lt;5 Years of Age in the United States, 1993–
2003. The Journal of Infectious Diseases 2007, 195(8), 1117–1125. https://doi.org/10.1086/512863 
Foster SO, Palmer EL, Gary GW, Martin ML, Herrmann KL, Beasley P, et al. Gastroenteritis Due to 
Rotavirus in an Isolated Pacific Island Group: An Epidemic of 3,439 Cases. Journal of Infectious 
Diseases 1980, 141(1), 32–39. https://doi.org/10.1093/infdis/141.1.32 
Gillespie SH, & Pearson RD. Principles and Practice of Clinical Parasitology.  Retrieved from 
https://leseprobe.buch.de/images-adb/24/f8/24f8f07e-620c-4e6e-952a-3f20faa4999 Principles and 
Practice of Clinical Parasitology 2001, John Wiley & Sons Ltd.pdf 
Goodgame RW. Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, 
isospora, and cyclospora. Annals of Internal Medicine 1996, 124(4), 429–41. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8554253 
Gray JJ, Kohli E, Ruggeri FM, Vennema H, Sánchez-Fauquier A, Schreier E, et al. European multicenter 
evaluation of commercial enzyme immunoassays for detecting norovirus antigen in fecal samples. 
Clinical and Vaccine Immunology : CVI 2007, 14(10), 1349–55. https://doi.org/10.1128/CVI.00214-
07 
Green KY, Ando T, Balayan MS, Berke T, Clarke IN, Estes MK., et al. Taxonomy of the caliciviruses. 
The Journal of Infectious Diseases 2000, 181 Suppl, S322-30. https://doi.org/10.1086/315591 
Greenberg HB & Estes MK. Rotaviruses: From Pathogenesis to Vaccination. Gastroenterology 2009, 
136(6), 1939–1951. https://doi.org/10.1053/j.gastro.2009.02.076 
Guix S, Asanaka M, Katayama K, Crawford SE, Neill FH, Atmar RL, et al. Norwalk Virus RNA Is 
Infectious in Mammalian Cells. Journal of Virology 2007, 81(22), 12238–12248. 
https://doi.org/10.1128/JVI.01489-07 
53 
 
Gutiérrez-Escolano AL, Brito ZU, del Angel RM & Jiang, X. Interaction of cellular proteins with the 5’ 
end of Norwalk virus genomic RNA. Journal of Virology 2000, 74(18), 8558–62. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=116368&tool=pmcentrez&rendertype=a
bstract 
Hall AJ, Eisenbart VG, Etingüe AL, Gould LH, Lopman BA & Parashar UD. Epidemiology of foodborne 
norovirus outbreaks, United States, 2001-2008. Emerging Infectious Diseases 2012, 18(10), 1566–
73. https://doi.org/10.3201/eid1810.120833 
Hall G, Kirk MD, Becker N, Gregory JE, Unicomb L, Millard G.. Estimating foodborne gastroenteritis, 
Australia. Emerging Infectious Diseases 2005, 11(8), 1257–64. 
https://doi.org/10.3201/eid1108.041367 
Hansman GS, Natori K, Shirato-Horikoshi H, Ogawa S, Oka T, Katayama K, et al . Genetic and antigenic 
diversity among noroviruses. Journal of General Virology 2006, 87, 909–919 
https://doi.org/10.1099/vir.0.81532-0 
Hardy ME. Norovirus protein structure and function. FEMS Microbiology Letters 253 (2005) 1–
8.https://doi.org/10.1016/j.femsle.2005.08.031 
Hasing ME, Lee BE, Preiksaitis JK., Tellier R, Honish L., Senthilselvan A, et al. Emergence of a new 
norovirus GII.4 variant and changes in the historial biennial pattern of norovirus outbreak activity in 
Alberta, Canada, from 2008 to 2013. Journal of Clinical Microbiology 2013, 51(7), 2204–11. 
https://doi.org/10.1128/JCM.00663-13 
Hassine-Zaafrane M, Sdiri-Loulizi K, Kaplon J, Salem IB, Pothier P, Aouni M, et al. Prevalence and 
genetic diversity of norovirus infection in Tunisian children (2007-2010). Journal of Medical 
Virology 2013, 85(6), 1100–10. https://doi.org/10.1002/jmv.23552 
Haustein T, Harris JP, Pebody R & Lopman BA. Hospital admissions due to norovirus in adult and 
elderly patients in England. Clinical Infectious Diseases : An Official Publication of the Infectious 
Diseases Society of America 2009, 49(12), 1890–2. https://doi.org/10.1086/648440 
Herbert TP, Brierley I & Brown TD. Detection of the ORF3 polypeptide of feline calicivirus in infected 
cells and evidence for its expression from a single, functionally bicistronic, subgenomic mRNA. The 
Journal of General Virology 1996, 77 ( Pt 1)(1), 123–7. https://doi.org/10.1099/0022-1317-77-1-
123 
Herbert TP, Brierley I & Brown TD. Identification of a protein linked to the genomic and subgenomic 
mRNAs of feline calicivirus and its role in translation. The Journal of General Virology 1997, 78 ( 
Pt 5), 1033–40. https://doi.org/10.1099/0022-1317-78-5-1033 
Hunter PR & Nichols G. Epidemiology and clinical features of Cryptosporidium infection in 
immunocompromised patients. Clinical Microbiology Reviews 2002, 15(1), 145–54. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11781272 
Jiang X, Wang J, Graham DY & Estes MK. Detection of Norwalk virus in stool by polymerase chain 
reaction. Journal of Clinical Microbiology 1992a, 30(10), 2529–34. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=270473&tool=pmcentrez&rendertype=a
bstract 
Jiang X, Wang M, Graham DY & Estes MK. Expression, self-assembly, and antigenicity of the Norwalk 
virus capsid protein. Journal of Virology 1992b, 66(11), 6527–32. Retrieved from 
54 
 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=240146&tool=pmcentrez&rendertype=a
bstract 
Jiang X, Wang M, Wang K & Estes MK. Sequence and genomic organization of Norwalk virus. Virology 
1993, 195(1), 51–61. https://doi.org/10.1006/viro.1993.1345 
Kapikian AZ. The discovery of the 27-nm Norwalk virus: an historic perspective. The Journal of 
Infectious Diseases 2000, 181 Suppl(Supplement 2), S295-302. https://doi.org/10.1086/315584 
Karst SM. Pathogenesis of noroviruses, emerging RNA viruses 2010. Viruses (Vol. 2). 
https://doi.org/10.3390/v2030748 
Karst SM, Wobus CE, Goodfellow IG, Green KY & Virgin HW. Advances in Norovirus Biology. Cell 
Host & Microbe 2014, 15(6), 668–680. https://doi.org/10.1016/j.chom.2014.05.015 
Karst SM, Wobus CE, Lay M, Davidson J & Virgin HW. STAT1-dependent innate immunity to a 
Norwalk-like virus. Science (New York, N.Y.) 2003, 299(5612), 1575–8. 
https://doi.org/10.1126/science.1077905 
Kirby A, Gurgel RQ, Dove W, Vieira SCF, Cunliffe NA & Cuevas LE. An evaluation of the 
RIDASCREEN and IDEIA enzyme immunoassays and the RIDAQUICK immunochromatographic 
test for the detection of norovirus in faecal specimens. Journal of Clinical Virology : The Official 
Publication of the Pan American Society for Clinical Virology 2010, 49(4), 254–7. 
https://doi.org/10.1016/j.jcv.2010.08.004 
Konno T, Suzuki H, Kutsuzawa T, Imai A, Katsushima N, Sakamoto M. Human rotavirus infection in 
infants and young children with intussusception. Journal of Medical Virology 1978, 2(3), 265–269. 
https://doi.org/10.1002/jmv.1890020310 
Koopmans M & Duizer E. Foodborne viruses: an emerging problem. International Journal of Food 
Microbiology 2004, 90(1), 23–41. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14672828 
Kotloff K, Nataro J, Blackwelder W, Nasrin D, Farag T, Panchalingam S. Burden and aetiology of 
diarrhoeal disease in infants and young children in developing countries (the Global Enteric 
Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013, 282(9888), 209–22. 
Kroneman A, Harris J, Vennema H, Duizer E, van Duynhoven Y, Gray J  et al. Data quality of 5 years of 
central norovirus outbreak reporting in the European Network for food-borne viruses. Journal of 
Public Health (Oxford, England) 2008, 30(1), 82–90. https://doi.org/10.1093/pubmed/fdm080 
Kroneman A, Vega E, Vennema H, Vinjé J, White PA, Hansman G, et al. Proposal for a unified norovirus 
nomenclature and genotyping. Archives of Virology 2013, 158(10), 2059–68. 
https://doi.org/10.1007/s00705-013-1708-5 
Krumkamp R, Sarpong N, Schwarz NG, Adlkofer J, Adelkofer J, Loag W, et al. Gastrointestinal 
infections and diarrheal disease in Ghanaian infants and children: an outpatient case-control study. 
PLoS Neglected Tropical Diseases 2015, 9(3), e0003568. 
https://doi.org/10.1371/journal.pntd.0003568 
Le Guyader F, Loisy F, Atmar RL, Hutson AM, Estes MK, Ruvoën-Clouet N, et al. Norwalk virus-
specific binding to oyster digestive tissues. Emerging Infectious Diseases 2016, 12(6), 931–6. 
Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2596755&tool=pmcentrez&rendertype=
55 
 
abstract 
Le Pendu J, Ruvoën-Clouet N, Kindberg E & Svensson L. Mendelian resistance to human norovirus 
infections. Seminars in Immunology 2006, 18(6), 375–86. 
https://doi.org/10.1016/j.smim.2006.07.009 
Leshem E, Moritz R, Curns A, Zhou F, Tate J, Lopman B & Parashar U. Rotavirus Vaccines and Health 
Care Utilization for Diarrhea in the United States. Pediatrics 2007, 134(15). 
https://doi.org/10.1542/peds.2013-3849 
Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, et al . Mechanisms of GII.4 
norovirus persistence in human populations. PLoS Medicine 2008, 5(2), e31. 
https://doi.org/10.1371/journal.pmed.0050031 
Lodder WJ, Vinjé J, van De Heide R, de Roda Husman AM, Leenen EJ & Koopmans MP. Molecular 
detection of Norwalk-like caliciviruses in sewage. Applied and Environmental Microbiology 1999, 
65(12), 5624–7. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10584031 
Lopman B. Global Burden of Norovirus and Prospects for Vaccine Development, 46. Retrieved from 
http://www.cdc.gov/norovirus/downloads/global-burden-report.pdf 
Lopman BA, Adak GK Reacher MH & Brown DWG. Two epidemiologic patterns of norovirus 
outbreaks: surveillance in England and wales, 1992-2000. Emerging Infectious Diseases 2003, 9(1), 
71–7. https://doi.org/10.3201/eid0901.020175 
Lopman BA, Reacher MH, Vipond IB, Hill D, Perry C, Halladay T et al. Epidemiology and cost of 
nosocomial gastroenteritis, Avon, England, 2002-2003. Emerging Infectious Diseases 2004, 10(10), 
1827–34. https://doi.org/10.3201/eid1010.030941 
Lopman B, Gastañaduy P, Park GW, Hall AJ, Parashar UD & Vinjé J. Environmental transmission of 
norovirus gastroenteritis. Current Opinion in Virology 2012, 2(1), 96–102. 
https://doi.org/10.1016/j.coviro.2011.11.005 
Lopman B, Simmons K, Gambhir M, Vinjé J & Parashar U. Epidemiologic implications of asymptomatic 
reinfection: a mathematical modeling study of norovirus. American Journal of Epidemiology 2014, 
179(4), 507–12. https://doi.org/10.1093/aje/kwt287 
Lopman B, Vennema H, Kohli E, Pothier P, Sanchez A, Negredo A, et al. Increase in viral gastroenteritis 
outbreaks in Europe and epidemic spread of new norovirus variant. Lancet (London, England) 2004, 
363(9410), 682–8. https://doi.org/10.1016/S0140-6736(04)15641-9 
Lopman, B., Zambon M & DW. The evolution of norovirus, the “gastric flu”. PLoS Medicine 2008, 5(2), 
e42. https://doi.org/10.1371/journal.pmed.0050042 
MacCannell T, Umscheid CA, Agarwal RK, Lee I, Kuntz G & Stevenson KB. Guideline for the 
prevention and control of norovirus gastroenteritis outbreaks in healthcare settings. Infection 
Control and Hospital Epidemiology 2011, 32(10), 939–69. https://doi.org/10.1086/662025 
Manabe, Y. C., Clark, D. P., Moore, R. D., Lumadue, Dahlman, H. R., Belitsos, P. C, et al. 
Cryptosporidiosis in Patients with AIDS: Correlates of Disease and Survival. Clinical Infectious 
Diseases 1998, 27(3), 536–542. https://doi.org/10.1086/514701 
Mans J, Armah GE, Steele AD, Taylor MBM, Ahmed S, Hall A, et al. Norovirus Epidemiology in Africa: 
A Review. PloS One  2016, 11(4), e0146280. https://doi.org/10.1371/journal.pone.0146280 
56 
 
Mans J, de Villiers J, du Plessis N, Avenant T, & Taylor M. Emerging norovirus GII.4 2008 variant 
detected in hospitalised paediatric patients in South Africa. Journal of  Clinical Virology 2010, 
49(4), 258–64. 
Marks PJ, Vipond IB, Carlisle D, Deakin D, Fey RE & Caul EO. Evidence for airborne transmission of 
Norwalk-like virus (NLV) in a hotel restaurant. Epidemiology and Infection 2000, 124(3), 481–7. 
Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2810934&tool=pmcentrez&rendertype=
abstract 
Marks PJ, Vipond IB, Regan FM, Wedgwood K, Fey RE & Caul EO. A school outbreak of Norwalk-like 
virus: evidence for airborne transmission. Epidemiology and Infection 2003, 131(1), 727–36. 
Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2870014&tool=pmcentrez&rendertype=
abstract 
Marthaler D, Rossow K, Culhane M, Goyal S, Collins J, Matthijnssens J. Widespread rotavirus H in 
commercially raised pigs, United States. Emerging Infectious Diseases 2014, 20(7), 1195–8. 
https://doi.org/10.3201/eid2007.140034 
Martins CA & Guerrant RL. Cryptosporidium and cryptosporidiosis. Parasitology Today (Personal Ed.) 
1995, 11(11), 434–6. https://doi.org/10.1016/0169-4758(95)80031-X 
Matthijnssens J, Ciarlet M, McDonald SM, Attoui H, Bányai K, Brister JR et al. Uniformity of rotavirus 
strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Archives of 
Virology 2011, 156(8), 1397–1413. https://doi.org/10.1007/s00705-011-1006-z 
McFadden N, Bailey D, Carrara G, Benson A, Chaudhry Y, Shortland A, et al. Norovirus regulation of 
the innate immune response and apoptosis occurs via the product of the alternative open reading 
frame 4. PLoS Pathogens 2011, 7(12), e1002413. https://doi.org/10.1371/journal.ppat.1002413 
Meeroff JC, Schreiber DS, Trier JS & Blacklow NR. Abnormal gastric motor function in viral 
gastroenteritis. Annals of Internal Medicine 1980, 92(3), 370–3. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/6766695 
Mengesha B. Cryptosporidiosis among medical patients with the acquired immunodeficiency syndrome 
in Tikur Anbessa Teaching Hospital, Ethiopia. East African Medical Journal 1994, 71(6), 376–8. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7835259 
Menon VK, George S, Aladin F, Nawaz S, Sarkar R, Lopman B, et al. Comparison of age-stratified 
seroprevalence of antibodies against norovirus GII in India and the United Kingdom. PloS One 
2013, 8(2), e56239. https://doi.org/10.1371/journal.pone.0056239 
Meyers G, Wirblich C & Thiel HJ. Genomic and subgenomic RNAs of rabbit hemorrhagic disease virus 
are both protein-linked and packaged into particles. Virology 1991, 184(2), 677–686. 
https://doi.org/10.1016/0042-6822(91)90437-G 
Morales M, Bárcena J, Ramírez MA, Boga JA, Parra F & Torres JM. Synthesis in vitro of rabbit 
hemorrhagic disease virus subgenomic RNA by internal initiation on (-)sense genomic RNA: 
mapping of a subgenomic promoter. The Journal of Biological Chemistry  2004, 279(17), 17013–8. 
https://doi.org/10.1074/jbc.M313674200 
Moreno-Espinosa S, Farkas T & Jiang X. Human caliciviruses and pediatric gastroenteritis. Seminars in 
57 
 
Pediatric Infectious Diseases 2004, 15(4), 237–245. https://doi.org/10.1053/j.spid.2004.07.004 
Morillo SG, Luchs A, Cilli A, Ribeiro CD, Calux SJ, Carmona R et al. Norovirus 3rd Generation kit: an 
improvement for rapid diagnosis of sporadic gastroenteritis cases and valuable for outbreak 
detection. Journal of Virological Methods 2011, 173(1), 13–6. 
https://doi.org/10.1016/j.jviromet.2010.12.017 
Moyo S, Hanevik K, Blomberg B, Kommedal O, Vainio K, Maselle S, et al. Genetic diversity of 
norovirus in hospitalised diarrhoeic children and asymptomatic controls in Dar es Salaam, Tanzania. 
Infect Genet Evol 2014., 26, 340–7. 
Nakagomi T. Rotavirus Infection and Intussusception: A View from Retrospect. Microbiology and 
Immunology 2000, 44(8), 619–628. https://doi.org/10.1111/j.1348-0421.2000.tb02542.x 
Noel JS, Fankhauser RL, Ando T, Monroe SS & Glass RI. Identification of a distinct common strain of 
“Norwalk-like viruses” having a global distribution. The Journal of Infectious Diseases 1999, 
179(6), 1334–44. https://doi.org/10.1086/314783 
Nordgren J, Nitiema LW, Ouermi D, Simpore J & Svensson L. Host genetic factors affect susceptibility 
to norovirus infections in Burkina Faso. PloS One 2013, 8(7), e69557. 
https://doi.org/10.1371/journal.pone.0069557 
Nurminen K, Blazevic V, Huhti L, Räsänen S, Koho T, Hytönen VP & Vesikari T. Prevalence of 
norovirus GII-4 antibodies in Finnish children. Journal of Medical Virology 2011, 83(3), 525–31. 
https://doi.org/10.1002/jmv.21990 
O’Donoghue PJ. Cryptosporidium and cryptosporidiosis in man and animals. International Journal for 
Parasitology 1995, 25(2), 139–95. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7622324 
Oluwatoyin JM, Adeyemi AO, Famurewa O, Svensson, L & Nordgren J. Molecular epidemiology of 
rotavirus and norovirus in Ile-Ife, Nigeria: high prevalence of G12P[8] rotavirus strains and 
detection of a rare norovirus genotype. Journal of Medical Virology 2012, 84(9), 1489–96. 
https://doi.org/10.1002/jmv.23343 
Ortega YR & Adam RD. Giardia: overview and update. Clinical Infectious Diseases : An Official 
Publication of the Infectious Diseases Society of America 1997, 25(3), 545–9; quiz 550. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/9314441 
OʼRyan M. The Ever-Changing Landscape of Rotavirus Serotypes. The Pediatric Infectious Disease 
Journal 2009, 28(Supplement), S60–S62. https://doi.org/10.1097/INF.0b013e3181967c29 
Palmer CJ, Xiao L, Terashima A, Guerra H, Gotuzzo E, Saldías G , et al. Cryptosporidium muris, a 
rodent pathogen, recovered from a human in Perú. Emerging Infectious Diseases 2003, 9(9), 1174–
6. https://doi.org/10.3201/eid0909.030047 
Parashar UD, Dow L, Fankhauser RL, Humphrey CD, Miller J, Ando T et al. An outbreak of viral 
gastroenteritis associated with consumption of sandwiches: implications for the control of 
transmission by food handlers. Epidemiology and Infection 1998, 121(3), 615–21. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2809569&tool=pmcentrez&rendertype=
abstract 
Patel MM, Hall AJ, Vinjé J & Parashar UD. Noroviruses: a comprehensive review. Journal of Clinical 
Virology : The Official Publication of the Pan American Society for Clinical Virology  2009, 44(1), 
58 
 
1–8. https://doi.org/10.1016/j.jcv.2008.10.009 
Patel MM, Tate JE, Selvarangan R, Daskalaki I, Jackson MA, Curns AT, et al. Routine Laboratory 
Testing Data for Surveillance of Rotavirus Hospitalizations to Evaluate the Impact of Vaccination. 
The Pediatric Infectious Disease Journal 2007, 26(10), 914–919. 
https://doi.org/10.1097/INF.0b013e31812e52fd 
Patel MM, Widdowson MAA, Glass RI, Akazawa K, Vinjé J & Parashar UDSystematic literature review 
of role of noroviruses in sporadic gastroenteritis. Emerging Infectious Diseases 2008, 14(8), 1224–
1231. https://doi.org/10.3201/eid1408.071114 
Patton JT. Rotavirus diversity and evolution in the post-vaccine world. Discovery Medicine 2012, 13(68), 
85–97. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22284787 
Payne DC, Vinjé J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, et al . Norovirus and medically 
attended gastroenteritis in U.S. children. The New England Journal of Medicine 2013, 368(12), 
1121–30. https://doi.org/10.1056/NEJMsa1206589 
Pediatric ROTavirus European CommitTee (PROTECT). The paediatric burden of rotavirus disease in 
Europe. Epidemiology and Infection 2006, 134(5), 908. 
https://doi.org/10.1017/S0950268806006091 
Phillips, G., Tam, C. C., Conti, S, Rodrigues LC, Brown D, Iturriza-Gomara M, et al. Community 
incidence of norovirus-associated infectious intestinal disease in England: improved estimates using 
viral load for norovirus diagnosis. American Journal of Epidemiology 2010, 171(9), 1014–22. 
https://doi.org/10.1093/aje/kwq021 
Pletneva MA, Sosnovtsev SV & Green KY. The genome of hawaii virus and its relationship with other 
members of the caliciviridae. Virus Genes 2001, 23(1), 5–16. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11556401 
Priest JW, Bern C, Xiao L, Roberts JM, Kwon JP, Lescano AG, et al. Longitudinal analysis of 
cryptosporidium species-specific immunoglobulin G antibody responses in Peruvian children. 
Clinical and Vaccine Immunology : CVI 2006, 13(1), 123–31. https://doi.org/10.1128/CVI.13.1.123-
131.2006 
Rackoff LA, Bok K, Green KY, & Kapikian AZ. Epidemiology and evolution of rotaviruses and 
noroviruses from an archival WHO Global Study in Children (1976-79) with implications for 
vaccine design. PloS One 2013, 8(3), e59394. https://doi.org/10.1371/journal.pone.0059394 
Reuter G, Krisztalovics K, Vennema H, Koopmans M & Szucs G. Evidence of the etiological 
predominance of norovirus in gastroenteritis outbreaks--emerging new-variant and recombinant 
noroviruses in Hungary. Journal of Medical Virology 2005, 76(4), 598–607. 
https://doi.org/10.1002/jmv.20403 
Rockx B, De Wit M, Vennema H, Vinjé J, De Bruin E, Van Duynhoven Y, et al . Natural history of 
human calicivirus infection: a prospective cohort study. Clinical Infectious Diseases : An Official 
Publication of the Infectious Diseases Society of America  2002, 35(3), 246–53. 
https://doi.org/10.1086/341408 
Saito M, Goel-Apaza S, Espetia S, Velasquez D, Cabrera L, Loli S. Multiple norovirus infections in a 
birth cohort in a Peruvian Periurban community. Clinical Infectious Diseases : An Official 
Publication of the Infectious Diseases Society of America 2014, 58(4), 483–91. 
59 
 
https://doi.org/10.1093/cid/cit763 
Santos N & Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the 
development and implementation of an effective rotavirus vaccine. Reviews in Medical Virology 
2005, 15(1), 29–56. https://doi.org/10.1002/rmv.448 
Satoskar AR, Simon GL, Hotez PJ & Tsuji M. Medical Parasitology. Retrieved from 
ftp://nozdr.ru/biblio/kolxo3/B/BH/Satoskar A.R., et al. Medical parasitology (Landes Bioscience, 
2009)(ISBN 1570596956)(O)(319s)_BH_.pdf 
Sdiri-Loulizi K, Ambert-Balay K, Gharbi-Khelifi H, Sakly N, Hassine M, Chouchane S, et al. Molecular 
epidemiology of norovirus gastroenteritis investigated using samples collected from children in 
Tunisia during a four-year period: detection of the norovirus variant GGII.4 Hunter as early as 
January 2003. Journal of Clinical Microbiology 2009, 47(2), 421–9. 
https://doi.org/10.1128/JCM.01852-08 
Shioda K, Kambhampati A, Hall AJ & Lopman BA. Global age distribution of pediatric norovirus cases. 
Vaccine 2015, 33(33), 4065–8. https://doi.org/10.1016/j.vaccine.2015.05.051 
Siebenga JJ, Vennema H, Zheng DP, Vinjé J, Lee BE, Pang XL, et al. Norovirus illness is a global 
problem: emergence and spread of norovirus GII.4 variants, 2001-2007. The Journal of Infectious 
Diseases 2009, 200(5), 802–12. https://doi.org/10.1086/605127 
Simmonds P, Karakasiliotis I, Bailey D, Chaudhry Y, Evans DJ & Goodfellow IG. Bioinformatic and 
functional analysis of RNA secondary structure elements among different genera of human and 
animal caliciviruses. Nucleic Acids Research 2008, 36(8), 2530–46. 
https://doi.org/10.1093/nar/gkn09 
Smit TK, Bos P, Peenze I, Jiang X, Estes MK & Steele AD. Seroepidemiological study of genogroup I 
and II calicivirus infections in South and southern Africa. Journal of Medical Virology 1999, 59(2), 
227–31. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10459161 
Son H, Jeong HS, Cho M, Lee J, Lee H, Yoon K, . Seroepidemiology of predominant norovirus strains 
circulating in Korea by using recombinant virus-like particle antigens. Foodborne Pathogens and 
Disease 2013, 10(5), 461–6. https://doi.org/10.1089/fpd.2012.1300 
Sosnovtsev SV, Belliot G, Chang KO, Prikhodko VG, Thackray LB, Wobus CE, et al . Cleavage map and 
proteolytic processing of the murine norovirus nonstructural polyprotein in infected cells. Journal of 
Virology 2006, 80(16), 7816–31. https://doi.org/10.1128/JVI.00532-06 
Tacket CO, Sztein MB, Losonsky GA, Wasserman SS & Estes MK. Humoral, mucosal, and cellular 
immune responses to oral Norwalk virus-like particles in volunteers. Clinical Immunology (Orlando, 
Fla.) 2003, 108(3), 241–7. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14499247 
Tan M, Huang P, Meller J, Zhong W, Farkas T & Jiang X. Mutations within the P2 Domain of Norovirus 
Capsid Affect Binding to Human Histo-Blood Group Antigens: Evidence for a Binding Pocket. 
Journal of Virology 2003, 77(23), 12562–12571. https://doi.org/10.1128/JVI.77.23.12562-
12571.2003 
Tan M & Jiang X. Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle. 
Trends in Microbiology 2005, 13(6), 285–93. https://doi.org/10.1016/j.tim.2005.04.004 
Tan M, Meller J & Jiang X. C-Terminal Arginine Cluster Is Essential for Receptor Binding of Norovirus 
60 
 
Capsid Protein. Journal of Virology 2006, 80(15), 7322–7331. https://doi.org/10.1128/JVI.00233-06 
Tan M, Xia M, Chen Y, Bu W, Hegde RS, Meller J. Conservation of carbohydrate binding interfaces: 
evidence of human HBGA selection in norovirus evolution. PloS One 2009, 4(4), e5058. 
https://doi.org/10.1371/journal.pone.0005058 
Taylor MB, Parker S, Grabow WO & Cubitt WD.. An epidemiological investigation of Norwalk virus 
infection in South Africa. Epidemiology and Infection 1996, 116(2), 203–6. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2271623&tool=pmcentrez&rendertype=
abstract 
Taylor MB, Schildhauer CI, Parker S, Grabow WO, Xi J, Estes MK, et al. Two successive outbreaks of 
SRSV-associated gastroenteritis in South Africa. Journal of Medical Virology  1993, 41(1), 18–23. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8228932 
Teunis PFM, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, et al. Norwalk virus: how infectious is 
it? Journal of Medical Virology 2008, 80(8), 1468–76. https://doi.org/10.1002/jmv.21237 
Thackray LB, Wobus CE, Chachu KA, Liu B, Alegre ER, Henderson KS, et al. Murine Noroviruses 
Comprising a Single Genogroup Exhibit Biological Diversity despite Limited Sequence Divergence. 
Journal of Virology 2007, 81(19), 10460–10473. https://doi.org/10.1128/JVI.00783-07 
Thorne LG & Goodfellow IG. Norovirus gene expression and replication. Journal of General Virology  
2014, 95(PART 2), 278–291. https://doi.org/10.1099/vir.0.059634-0 
Tomov VT, Osborne LC, Dolf DV, Sonnenberg GF, Monticelli LA, Mansfield K, et al. Persistent enteric 
murine norovirus infection is associated with functionally suboptimal virus-specific CD8 T cell 
responses. Journal of Virology 2013, 87(12), 7015–31. https://doi.org/10.1128/JVI.03389-12 
Trainor E, Lopman B, Iturriza-Gomara M, Dove W, Ngwira B, Nakagomi O et al. Detection and 
molecular characterisation of noroviruses in hospitalised children in Malawi, 1997-2007. Journal of 
Medical Virology  2013, 85(7), 1299–306. https://doi.org/10.1002/jmv.23589 
Trimis G, Koutsoumbari I, Kottaridi C, Palaiologou N, Assimakopoulou E, Spathis A, et al. Hospital-
based surveillance of rotavirus gastroenteritis in the era of limited vaccine uptake through the 
private sector. Vaccine  2011, 29(43), 7292–5. https://doi.org/10.1016/j.vaccine.2011.07.092 
Trivedi TK, DeSalvo T, Lee L, Palumbo A, Moll M, Curns A, et al. Hospitalizations and Mortality 
Associated With Norovirus Outbreaks in Nursing Homes, 2009-2010. JAMA 2012, 308(16), 1668. 
https://doi.org/10.1001/jama.2012.14023 
Tu ETV, Bull RA, Greening GE, Hewitt J, Lyon MJ, Marshall JA, et al. Epidemics of gastroenteritis 
during 2006 were associated with the spread of norovirus GII.4 variants 2006a and 2006b. Clinical 
Infectious Diseases : An Official Publication of the Infectious Diseases Society of America  2008, 
46(3), 413–20. https://doi.org/10.1086/525259 
Ungar BLP. Cryptosporidiosis in humans (Homo sapiens). Cryptosporidiosis of Man and Animals  1990., 
59–82. Retrieved from https://www.cabdirect.org/cabdirect/abstract/19910875517 
Verhoef L, Koopmans M, van Pelt W, Duizer E, Haagsma J, Werber D. The estimated disease burden of 
norovirus in The Netherlands. Epidemiology and Infection  2013, 141(3), 496–506. 
https://doi.org/10.1017/S0950268812000799 
Vinjé J. Advances in laboratory methods for detection and typing of norovirus. Journal of Clinical 
61 
 
Microbiology 2015, 53(2), 373–81. https://doi.org/10.1128/JCM.01535-14 
Wakuda M, Ide T, Sasaki J, Komoto S, Ishii J, Sanekata T, et al. Porcine rotavirus closely related to novel 
group of human rotaviruses. Emerging Infectious Diseases 2011, 17(8), 1491–3. 
https://doi.org/10.3201/eid1708.101466 
White KE, Osterholm MT, Mariotti JA, Korlath JA, Lawrence DH., Ristinen, T. L, et al. A foodborne 
outbreak of Norwalk virus gastroenteritis. Evidence for post-recovery transmission. American 
Journal of Epidemiology 1986, 124(1), 120–6. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/3013001 
White PA, Hansman GS, Li A, Dable J, Isaacs M, Ferson M, et al. Norwalk-like virus 95/96-US strain is 
a major cause of gastroenteritis outbreaks in Australia. Journal of Medical Virology 2002, 68(1), 
113–8. https://doi.org/10.1002/jmv.101 
White PA. Evolution of norovirus. Clinical Microbiology and Infection 2014; 20(8): 741–5. 
https://doi.org/10.1111/1469-0691.12746. 
Widdowson MA, Cramer EH, Hadley L, Bresee JS, Beard RS, Bulens SN,et al. Outbreaks of acute 
gastroenteritis on cruise ships and on land: identification of a predominant circulating strain of 
norovirus--United States, 2002. The Journal of Infectious Diseases 2004, 190(1), 27–36. 
https://doi.org/10.1086/420888 
Wikswo ME & Hall AJ. Outbreaks of Acute Gastroenteritis Transmitted by Person-to-Person Contact — 
United States, 2009–2010, 61(SS09), 1–12. 
Wilhelmi I, Roman E & Sanchez-Fauquier A. Viruses causing gastroenteritis. Clinical Microbiology and 
Infection  2003, 9(4), 247–262. https://doi.org/10.1046/j.1469-0691.2003.00560.x 
Wolfaardt M, Taylor MB, Booysen HF, Engelbrecht L, Grabow WO & Jiang X. Incidence of human 
calicivirus and rotavirus infection in patients with gastroenteritis in South Africa. Journal of 
Medical Virology 1997, 51(4), 290–6. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9093943 
Wolfe MS.. Giardiasis. Clinical Microbiology Reviews 1992, 5(1), 93–100. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/1735095 
Xi JN, Graham DY, Wang KN & Estes MK. Norwalk virus genome cloning and characterization. Science 
(New York, N.Y.)  1990, 250(4987), 1580–3. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/2177224 
Xiao L, Faye, R, Ryan U & Upton SJ. Cryptosporidium taxonomy: recent advances and implications for 
public health. Clinical Microbiology Reviews 2004, 17(1), 72–97. 
https://doi.org/10.1128/CMR.17.1.72-97.2004 
Yen C, Wikswo ME, Lopman BA, Vinje J, Parashar UD & Hall AJ. Impact of an emergent norovirus 
variant in 2009 on norovirus outbreak activity in the United States. Clinical Infectious Diseases : An 
Official Publication of the Infectious Diseases Society of America 2011, 53(6), 568–71. 
https://doi.org/10.1093/cid/cir478 
Zahorsk J. Hyperemesis hiemis or the winter vomiting disease. Arch Pediatr 1929, (46), 391–395. 
Zheng DP, Ando T, Fankhauser RL., Beard RS, Glass RI. & Monroe SS. Norovirus classification and 
proposed strain nomenclature. Virology 2006, 346(2), 312–23. 
62 
 
https://doi.org/10.1016/j.virol.2005.11.015 
(UK), N. C. C. for W. and C. H. Fluid management. Diarrhoea and vomiting caused by gastroenteritis 
diagnosis, assessment and management in children younger than 5 years (Vol. 84). RCOG Press 
(2009). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK63837/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
APPENDICES 
APPENDEX I: Consent Form 
 
The study has been explained to me in detail and I grant permission for stool specimen to be collected 
from my child/ward. The stool specimen will be examined for germs causing diarrhoea and medicines 
that may kill these germs.  
Yes........... No.................  
I give permission for the doctor/nurse to record the HIV status of my child/ward on the information sheet 
and I understand that this information will not be linked to my child’s name.  
Yes............      No...................  
I grant permission for a blood specimen to be collected from my child/ward and examined for HIV if this 
result is not available in his/her file   
Yes........... No.................  
I grant permission for a blood specimen to be collected from my child/ward and examined for antibody 
levels against some germs that cause diarrhoea.  
Yes........... No.................  
We hereby declare that we do not intend to export or sell the collected specimens for commercial 
purposes   
  
Name of Parent/Guardian:      Name of Doctor/Nurse  
  
--------------------------------------                                      ---------------------------------------  
  
Signature---------------------------------            Signature-------------------------------  
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Date: _______________________  
  
Name of Translator (if applicable)  
  
Signature--------------------------------  
  
NB: This sheet is to be removed by the study coordinator upon completion of enrolment and delivered in  
a sealed envelope to the principal investigator. The forms will be stored in a separate, locked cabinet and 
destroyed when the study is officially closed.  
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APPENDEX II: Questionnaire 
 
Patient no.     
Date of birth (dd/mm/yy)  
Date of admission 
Date of specimen collection                                                                    No specimen  
Is the stool 
                          Watery      
                           Bloody 
                           Unknown  
 
Age              
Gender                         
 
Weight            kg                                        centile 
Height                                             kg                                         centile 
 
 HIV status 
 On ART? 
 
CD4 count/ percentage  
How long does the patient have diarrhea for  
 
 Is the child underweight for age? 
Does the child have kwashiorkor? 
 
Has the child received immunizations to date? 
 
 
 
M F 
 
P N Exposed Unexposed Unknown 
Y N 
Y N 
Y N 
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Birth BCG  
OPV  
6 weeks OPV  
RV (1)  
DTaP-IPV/Hib (1)  
Hep B (1)  
PCV (1)   
10 weeks DTaP-IPV/Hib (2)   
Hep B (2)   
14 weeks RV (2)   
DTaP-IPV/Hib (3)   
Hep B (3)   
PCV (2)   
9 months Measles (1)   
PCV (3)   
18 months DTaP-IPV/Hib (4)   
Measles (2)   
 
How many doses has of vitamin A has the child received  
Has the child received Zinc supplementation? 
YES       YES                                        NO                                  UNKNOWN 
 
Has the child received Anti-helminthic? 
 
 
If child < 6 months, is the child 
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What is the water supply at home? 
Piped water in dwelling  
Piped water on site  
Neighbor’s tap  
Communal tap  
Rainwater  
Borehole on site  
River /stream /flowing  
Dam /pool /stagnant water  
Well  
Spring  
Other  
                                                                                           Specify 
 
Type of sanitation 
Flush  
VIP  
Urine-diversion  
Other  
                                                                                        Specify 
                 
Exclusively breastfed  
Formula-fed  
Mixed fed  
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Availability of soap to wash hands 
Always  
Sometimes  
Never  
 
Current treatment 
 
 
 
 
 
Any treatment prior to coming to this clinic/hospital 
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APPENDEX III: Ethics Certificates 
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